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USE OF PARTHENOLIDE DERIVATIVES AS 
ANTILEUKEMIC AND CYTOTOXIC 
AGENTS 
2 
This is a divisional application of U.S. patent application 5 
Ser. No. 14/270,121, filed May 5, 2014, which is a divisional 
application of U.S. patent application Ser. No. 13/925,219, 
filed Jun. 24, 2013, issued May 6, 2014 as U.S. Pat. No. 
8,716,329, which is a divisional application of U.S. patent 
application Ser. No. 13/372,178, filed Feb. 13, 2012, now 10 
U.S. Pat. No. 8,470,875, issued Jun. 25, 2013, which is a 
divisional of U.S. patent application Ser. No. 12/693,161, 
filed Jan. 25, 2010, now U.S. Pat. No. 8,124,652, which is 
thenolide (1 ). Recently, it has been revealed that 
parthenolide (1) can induce tumor apoptosis by the inhibi-
tion of NF-KB activities (Cory eta!., Anticancer Research 
2002, 22, 3805-9; Cory eta!., Anticancer Research 2001, 21, 
3807-11; Gelfanov eta!., Blood, 2000, 98, 2508-17; Kang et 
a!, Brit. J. Pharmacal. 2002, 135, 1235-44; Song et a!., J. 
Asian. Nat. Prod. Res. 2001, 3, 285-91). 
Parthenolide (1) is a lipophilic, neutral lactone with low 
polarity, and has a low water-solubility, limiting its devel-
opment as a therapeutic agent. Thus, a need exists for the 
development of soluble parthenolide derivatives that retain 
their anti-cancer activity. 
SUMMARY OF THE INVENTION 
a divisional application of U.S. patent application Ser. No. 
15 
11/031,315 filed Jan. 7, 2005, now U.S. Pat. No. 7,678,904, 
which is a continuation-in-part of U.S. patent application 
Ser. No. 10/888,274 filed Jul. 9, 2004, now U.S. Pat. No. 
In accordance with the present invention, a novel class of 
compounds with antileukemic activity is presented. Accord-
ingly, the present invention provides compounds of formula 
(I): 7 ,312,242, which claims the benefit of priority to provisional 
application No. 60/486,171 filed Jul. 11, 2003. 20 
FIELD OF THE INVENTION (I) 
The present invention relates to methods for the structural 
modification of the sesquiterpene lactone, parthenolide, and 
25 
the use of these parthenolide derivatives in the treatment of 
carcinoma. More specifically, the invention relates to the 
methods to prepare structural analogs of the parent com-
pound, parthenolide, in order to obtain new, pharmacologi-
cally active chemical entities with improved water solubility 
30 
characteristics, and to use them in the treatment ofleukemias 
and other parental and multi-drug resistant cancers 
z 
BACKGROUND OF THE INVENTION 
Sesquiterpene lactones are a group of secondary plant 
metabolites consisting of a 15-carbon structure containing 
an a-methylene-y-butyrolactone moiety and other additional 
functional groups. Over the last two to three decades, these 
terpenoids have received considerable attention due to the 
broad spectrum of their biological activities, to the plants 
which produce them, and most importantly, because of their 
pharmacological effects in humans. About 4,000 of these 
terpenoids have been isolated and identified, most of them in 
Asteraceae (Compositae, sunflower family) (Schmidt, Curr. 
Org. Chern. 1999, 3, 577-608). Some of these plants have 
been used for centuries in indigenous medical practices in 
various cultures worldwide. 
Parthenolide (1) is a Germacrane sesquiterpene lactone 
with a unique structure. It has been isolated from several 
different species in Asteraceae (Compositae) family, fever-
few (Tanacetum parthenium) being one of them. 
13 
0 
Feverfew has been used to reduce fever and pain and in 
the treatment of migraine and rheumatoid arthritis (Heptin-
stall et a!., ACS Symposium Series (1998), 691 (Phytomedi-
cines of Europe), 158-175). The active component is par-
35 
wherein: 
X1 , X2 and X3 are heteroatoms; 
R4 , R5 , R6 , R7 , R8 , R9 and R10 are independently selected 
from H, halo, ---OH, -N02 , ---CN and optionally substi-
tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het-
eroaryl; and 
Z is optionally substituted C1_8 straight-chained or branched 
40 aliphatic, optionally containing 1 or more double or triple 
bonds, wherein one or more carbons are optionally replaced 
by R * wherein R * is optionally substituted cycloalkyl, 
heterocycloalkyl, aryl or heteroaryl; an amino acid residue, 
H, -CN, -C(O)-, -C(O)C(O)-, -C(O)NR1-, 
45 ---C(O)NR1NR2-, ---C(O)O-, ---OC(O)-, 
-NR1C02-, ---0-, -NR
1C(O)NR2-, ---OC(O) 
NR1-, -NR1NR2-, -NR1C(O)-, -S-, -SO-, 
-S02-, -NR
1
-, -S02 NR
1
-, -NR1R2 , or 
-NR 1 S02-, wherein R 
1 and R 2 are independently selected 
50 from H and optionally substituted aliphatic, cycloalkyl, 
heterocycloalkyl, aryl or heteroaryl; or where R * is NR 1 R2 , 
R1 and R2 optionally together with the nitrogen atom form 
an optionally substituted 5-12 membered ring, said ring 
optionally comprising 1 or more heteroatoms and/or a group 
55 selected from -CO-, -SO-, -S02 - and -PO-; or 
a pharmaceutically acceptable salt, ester or prodrug 
thereof. 
The invention also provides a pharmaceutical composi-
tion comprising an effective amount of a compound of 
60 formula (I), or a pharmaceutically acceptable salt, ester or 
prodrug thereof, in combination with a pharmaceutically 
acceptable diluent or carrier. 
The invention also provides a method of inhibiting cancer 
cell growth and metastasis of cancer cells, comprising 
65 administering to a mammal afflicted with cancer, an amount 
of a compound of formula (I), effective to inhibit the growth 
of said cancer cells. 
US 9,447,112 B2 
3 
The invention also provides a method comprising inhib-
iting cancer cell growth by contacting said cancer cell in 
vitro or in vivo with an amount of a compound of formula 
(I), effective to inhibit the growth of said cancer cell. 
The invention also provides a compound of formula (I) 
for use in medical therapy (preferably for use in treating 
cancer, e.g. solid tumors), as well as the use of such 
compound for the manufacture of a medicament useful for 
the treatment of cancer and other diseases/disorders 
described herein. 
The invention further provides methods of treating 
inflammatory diseases and disorders, including, for 
example, rheumatoid arthritis, osteoarthritis, allergies (such 
as asthma), and other inflammatory conditions, such as pain 
(such as migraine), swelling, fever, psoriasis, inflammatory 
bowel disease, gastrointestinal ulcers, cardiovascular condi-
tions, including ischemic heart disease and atherosclerosis, 
partial brain damage caused by stroke, skin conditions 
(eczema, sunburn, acne), leukotriene-mediated inflamma-
tory diseases of lungs, kidneys, gastrointestinal tract, skin, 
prostatitis and paradontosis. 
The invention further provides methods of treating 
immune response disorders, whereby the immune response 
is inappropriate, excessive or lacking. Such disorders 
include allergic responses, transplant rejection, blood trans-
fusion reaction, and autoimmune disorders such as systemic 
lupus erythematosus and rheumatoid arthritis. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the effectiveness of parthenolide and deriva-
tives of the present invention against prostate cancer cell line 
CWR22 in a clonogenic assay. 
FIG. 2 shows the effectiveness of parthenolide and deriva-
tives of the present invention against lung cancer cell line 
A-549 in a cellular proliferation MTS-PMS assay. 
FIG. 3 shows the effectiveness of parthenolide and deriva-
tives of the present invention against lung cancer cell line 
H-522 in a cellular proliferation MTS-PMS assay. 
FIG. 4 shows the effectiveness of parthenolide and deriva-
tives of the present invention against lung cancer cell line 
H-23 in a cellular proliferation MTS-PMS assay. 
10 
4 
FIG. 12 shows FSCScan analysis of TRAIL induced 
apoptosis assay using MDA-MB-231 breast cancer cells 
treated first with DMAPT, then TRAIL. 
DETAILED DESCRIPTION OF THE 
INVENTION 
As used herein, the following definitions shall apply 
unless otherwise indicated. 
The phrase "optionally substituted" is used interchange-
ably with the phrase "substituted or unsubstituted." Unless 
otherwise indicated, an optionally substituted group may 
have a substituent at each substitutable position of the group, 
15 
and each substitution is independent of any other. Also, 
combinations of substituents or variables are permissible 
only if such combinations result in stable compounds. In 
addition, unless otherwise indicated, functional group radi-
cals are independently selected. Where "optionally substi-
20 tuted" modifies a series of groups separated by commas 
(e.g., "optionally substituted A, B or C"; or "A, B or C 
optionally substituted with"), it is intended that each of the 
groups (e.g., A, B and C) is optionally substituted. 
The term "aliphatic" or "aliphatic group" as used herein 
25 means a straight-chain or branched C1_12 hydrocarbon chain 
that is completely saturated or that contains one or more 
units of unsaturation, or a monocyclic C3 _8 hydrocarbon or 
bicyclic C8 _12 hydrocarbon that is completely saturated or 
that contains one or more units ofunsaturation, but which is 
30 not aromatic (also referred to herein as "carbocycle" or 
"cycloalkyl"), that has a single point of attachment to the 
rest of the molecule wherein any individual ring in said 
bicyclic ring system has 3-7 members. For example, suitable 
aliphatic groups include, but are not limited to, linear or 
35 branched or alkyl, alkenyl, alkynyl groups and hybrids 
thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or 
( cycloalkyl)alkenyl. 
The terms "alkyl," "alkoxy," "hydroxyalkyl," "alkoxy-
alkyl" and "alkoxycarbonyl," used alone or as part of a 
40 larger moiety include both straight and branched chains 
containing one to twelve carbon atoms. The terms "alkenyl" 
and "alkynyl" used alone or as part of a larger moiety shall 
include both straight and branched chains containing two to 
twelve carbon atoms. 
FIG. 5 shows the effectiveness of parthenolide and deriva- 45 
tives of the present invention against lung cancer cell line 
H-460 in a cellular proliferation MTS-PMS assay. 
The terms "haloalkyl," "haloalkenyl" and "haloalkoxy" 
means alkyl, alkenyl or alkoxy, as the case may be, substi-
tuted with one or more halogen atoms. The term "halogen" 
or "halo" means F, Cl, Br or I. FIG. 6 shows the effectiveness of parthenolide and deriva-
tives of the present invention against breast cancer cell line 
HBL-1 00 in a clonogenic assay. 
FIG. 7 shows the effectiveness of parthenolide and deriva-
tives of the present invention against breast cancer cell line 
MD-231 in a clonogenic assay. 
FIG. 8 shows the effectiveness of parthenolide and deriva-
tives of the present invention against breast cancer cell line 
MD-436 in a clonogenic assay 
FIG. 9 shows parthenolide and DMAPT plasma concen-
trations at one hour following oral gavage in mice. 
FIG. 10 shows DMAPT dose-dependent inhibition of 
NF -kB DNA binding in two transitional cell carcinoma cell 
lines HT-1376 and UMUC-3 in electrophoretic mobility gel 
shift assay (EMSA). 
FIG. 11 shows FSCScan analysis of TRAIL induced 
apoptosis assay using MDA-MB-231 breast cancer cells 
treated first with DMAPT, then TRAIL-RII-activating anti-
bodies. 
The term "heteroatom" means nitrogen, oxygen, or sulfur 
50 and includes any oxidized form of nitrogen and sulfur, and 
the quatemized form of any basic nitrogen. Heteroatom 
further includes Se, Si and P. 
The term "aryl" used alone or in combination with other 
terms, refers to monocyclic, bicyclic or tricyclic carbocyclic 
55 ring systems having a total of five to fourteen ring members, 
wherein at least one ring in the system is aromatic and 
wherein each ring in the system contains 3 to 8 ring 
members. The term "aryl" may be used interchangeably with 
the term "aryl ring". The term "aralkyl" refers to an alkyl 
60 group substituted by an aryl. The term "aralkoxy" refers to 
an alkoxy group substituted by an aryl. 
The term "heterocycloalkyl," "heterocycle," "heterocy-
clyl" or "heterocyclic" as used herein means monocyclic, 
bicyclic or tricyclic ring systems having five to fourteen ring 
65 members in which one or more ring members is a heteroa-
tom, wherein each ring in the system contains 3 to 7 ring 
members and is non-aromatic. 
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The term "heteroaryl," used alone or in combination with 
other terms, refers to monocyclic, bicyclic and tricyclic ring 
systems having a total of five to fourteen ring members, and 
wherein: 1) at least one ring in the system is aromatic; 2) at 
least one ring in the system contains one or more heteroa- 5 
toms; and 3) each ring in the system contains 3 to 7 ring 
members. The term "heteroaryl" may be used interchange-
ably with the term "heteroaryl ring" or the term "heteroaro-
matic". Examples of heteroaryl rings include 2-furanyl, 
3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imi- 10 
dazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiaz-
olyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 
1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 3-pyrazolyl, 
4-pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 
4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 2-thiazolyl, 4-thi- 15 
azolyl, 5-thiazolyl, 5-tetrazolyl, 2-triazolyl, 5-triazolyl, 
2-thienyl, 3-thienyl, carbazolyl, benzimidazolyl, benzothie-
nyl, benzofuranyl, indolyl, quinolinyl, benzotriazolyl, ben-
zothiazolyl, benzooxazolyl, benzimidazolyl, isoquinolinyl, 
indazolyl, isoindolyl, acridinyl, and benzoisoxazolyl. The 20 
term "heteroaralkyl" refers to an alkyl group substituted by 
a heteroaryl. The term "heteroarylalkoxy" refers to an 
alkoxy group substituted by a heteroaryl. \ 
An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the 
like) or heteroaryl (including heteroaralkyl, heteroarylal- 25 
koxy and the like) group may contain one or more substitu-
ents. Suitable substituents on an unsaturated carbon atom of 
an aryl, heteroaryl, aralkyl or heteroaralkyl group are 
selected from halogen; haloalkyl; ---CF3 ; -R; -OR; 
-SR; 1,2-methylenedioxy; 1,2-ethylenedioxy; protected 30 
OH (such as acyloxy); phenyl (Ph); Ph substituted with R; 
-O(Ph); -0-(Ph) substituted with R; ---CH2 (Ph); -CH2 
(Ph) substituted with R; -CH2CH2 (Ph); -CH2CH2 (Ph) 
substituted with R; -N02 ; ---CN; -N(R)2 ; -NRC(O)R; 
-NRC(O)N(R)2 ; -NRC02 R; -NRNRC(O)R; -NR- 35 
NRC(O)N(R)2 ; -NRNRC02R; ---C(O)C(O)R; ---C(O) 
CH2 C(O)R; -C02R; -C(O)R; -C(O)N(R)2 ; ---OC(O)N 
(R)2 ; -S(0)2R; -S02N(R)2 ; -S(O)R; -NRS02N(R)2 ; 
-NRS02 R; ---C(=S)N(R)2 ; -C(=NH)-N(R)2 ; 
-(CH2)yNHC(O)R; -(CH2 )yR; -(CH2 )yNHC(O)NHR; 40 
-(CH2)yNHC(O)OR; -(CH2)yNHS(O)R; -(CH2 )y 
NHS02R; or -(CH2 )yNHC(O)CH((V)2 -R)(R) wherein 
each R is independently selected from hydrogen, optionally 
substituted C1 _6 aliphatic, an unsubstituted 5-6 membered 
heteroaryl or heterocyclic ring, phenyl (Ph), ---O(Ph), or 45 
-CH2 (Ph)-CH2 (Ph), wherein y is 0-6; z is 0-1; and Vis a 
linker group. When R is C1 _6 aliphatic, it may be substituted 
with one or more substituents selected from -NH2 , -NH 
(C1-4 aliphatic), -N(C1_4 aliphatic)2 , -S(O)(C1_4 ali-
phatic), -S02 (C1 _4 aliphatic), halogen, (C1 -4 aliphatic), 50 
-OH, ---O(C1_4 aliphatic), -N02 , -CN, ---C02 H, -C02 
(C1-4 aliphatic), ---O(halo C1 _4 aliphatic), or 
-halo(C1 _4 aliphatic); wherein each C1_4 aliphatic is option-
ally. 
An aliphatic group or a non-aromatic heterocyclic ring 55 
may contain one or more substituents. Suitable substituents 
on a saturated carbon of an aliphatic group or of a non-
aromatic heterocyclic ring are selected from those listed 
above for the unsaturated carbon of an aryl or heteroaryl 
group and the following: =0, =S, =NNHR, NN(R)2 , 60 
=N-, NNHC(O)R, NNHC02 (alkyl), =NNHS02 
(alkyl), or NR, where each R is independently selected 
from hydrogen or an optionally substituted C1_6 aliphatic. 
When R is C1_6 aliphatic, it may be substituted with one or 
more substituents selected from -NH2 , -NH(C1_4 ali- 65 
phatic), -N(C1_4 aliphatic)2 , halogen, ---OH, -O-(C1 _4 
aliphatic), -N02 , ---CN, -C02H, ---C02 (C1 _4 aliphatic), 
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---O(halo C1_4 aliphatic), or -halo(C1 _4 aliphatic); wherein 
each C1 _4 aliphatic is optionally substituted. 
Substituents on a nitrogen of a non-aromatic heterocyclic 
ring are selected from 
-R, -N(R)2 , -C(O)R, -C(O)OR, ---C(O)C(O)R, 
---C(O)CH2 C(O)R, -S02R, -S02N(R)2 , ---C(=S)N(R)2 , 
---C( NH)-N(R)2 or -NRS02 R; wherein each R is inde-
pendently selected from hydrogen, an optionally substituted 
C1_6 aliphatic, optionally substituted phenyl (Ph), optionally 
substituted ---O(Ph), optionally substituted -CH2 (Ph), 
optionally substituted -CH2CH2 (Ph), or an unsubstituted 
5-6 membered heteroaryl or heterocyclic ring. When R is a 
C1_6 aliphatic group or a phenyl ring, it may be substituted 
with one or more substituents selected from -NH2 , -NH 
(C1 -4 aliphatic), -N(C1 _4 aliphatic)2 , halogen, -(C1 -4 ali-
phatic), -OH, ---O-(C1_4 aliphatic), -N02 , -CN, 
---C02 H, -C02 (C1_4 aliphatic), ---O(halo C1 _4 aliphatic) or 
-halo(C1 _4 aliphatic); wherein each C1_4 aliphatic is option-
ally substituted. 
The term "linker group" or "linker" means an organic 
moiety that connects two parts of a compound. Linkers 
include alkylidene chain that is a saturated or unsaturated, 
straight or branched, C1_8 carbon chain which is optionally 
substituted, and wherein up to two non-adjacent saturated 
carbons of the chain are optionally replaced by R * wherein 
R * is ---C(O)-, ---C(O)C(O)-, -C(O)NR-, ---C(O) 
NRNR-, ---C(O)O-, -OC(O)-, -NRC02-, ---0-, 
-NRC(O)NR-, -OC(O)NR-, -NRNR-, -NRC 
(0)-, -S-, -SO-, -S02-, -NR-, -S02NR-, or 
-NRS02-; wherein R is selected from hydrogen or 
optionally substituted aliphatic, cycloalkyl, heterocy-
cloalkyl, aryl or heteroaryl, and preferably H or optionally 
substituted C1_4 aliphatic. Optional substituents on the alky-
lidene chain are as described above for an aliphatic group. 
Alternatively, the linker group is R *. 
The term "treatment" refers to any treatment of a patho-
logic condition in a mammal, particularly a human, and 
includes: (i) preventing the pathologic condition from occur-
ring in a subject which may be predisposed to the condition 
but has not yet been diagnosed with the condition and, 
accordingly, the treatment constitutes prophylactic treatment 
for the disease condition; (ii) inhibiting the pathologic 
condition, i.e., arresting its development; (iii) relieving the 
pathologic condition, i.e., causing regression of the patho-
logic condition; or (iv) relieving the conditions mediated by 
the pathologic condition. 
The term "therapeutically effective amount" refers to that 
amount of a compound of the invention that is sufficient to 
effect treatment, as defined above, when administered to a 
mammal in need of such treatment. The therapeutically 
effective amount will vary depending upon the subject and 
disease condition being treated, the weight and age of the 
subject, the severity of the disease condition, the manner of 
administration and the like, which can readily be determined 
by one of ordinary skill in the art. 
The term "pharmaceutically acceptable salts" includes, 
but is not limited to, salts well known to those skilled in the 
art, for example, mono-salts (e.g. alkali metal and ammo-
nium salts) and poly salts (e.g. di- or tri-salts) of the 
compounds of the invention. Pharmaceutically acceptable 
salts of compounds of formulas (I), (II), (III), or (IV) are 
where, for example, an exchangeable group, such as hydro-
gen in -OH, -NH-, or -P(=O)(OH)-, is replaced 
with a pharmaceutically acceptable cation (e.g. a sodium, 
potassium, or ammonium ion) and can be conveniently be 
prepared from a corresponding compound of formula (I) by, 
for example, reaction with a suitable base. In cases where 
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compounds are sufficiently basic or acidic to form stable 
nontoxic acid or base salts, administration of the compounds 
8 
as salts may be appropriate. Examples of pharmaceutically 
acceptable salts are organic acid addition salts formed with 
acids that form a physiological acceptable anion, for 
example, tosylate, methanesulfonate, acetate, citrate, 
malonate, tartarate, succinate, benzoate, ascorbate, a-keto-
glutarate, and a-glycerophosphate. Suitable inorganic salts 
may also be formed, including hydrochloride, sulfate, 
nitrate, bicarbonate, and carbonate salts. 
Pharmaceutically acceptable salts include quaternary 
ammonium salts formed with R'Y; where Y is selected from 
halogen, tosylate, methanesulfonate, benzenesulfonate, trif-
luoromethanesulfonate and the like; and R' is selected from 
an optionally substituted cycloalkyl, heterocycloalkyl, aryl 
or heteroaryl. 
a!., 1996 Antiviral Research 31:59-67), both of which are 
incorporated in their entirety herein by reference. Additional 
examples of suitable prodrug technology is described in WO 
90/00555; WO 96/39831; WO 03/095665A2; U.S. Pat. Nos. 
5,411,947; 5,463,092; 6,312,662; 6,716,825; and U.S. Pub-
lished Patent Application Nos. 2003/0229225 and 2003/ 
0225277 each of which is incorporated in their entirety 
herein by reference. Such prodrugs may also possess the 
ability to target the drug compound to a particular tissue 
10 within the patient, e.g., liver, as described by Erion et a!., 
(2004 J. Am. Chern. Soc. 126:5154-5163; Erion eta!., Am. 
Soc. Pharm. & Exper. Ther. DOI:10.1124/jept.104.75903 
(2004); WO 01/18013 A1; U.S. Pat. No. 6,752,981), each of 
15 
which is incorporated in their entirety herein by reference. 
By way of non-limiting example, other prodrugs suitable for 
use with the compounds of the invention are described in 
WO 03/090690; and by Harris et a!., (2002 Antiviral 
Chern & Chemo. 12: 293-300; Knaggs et a!., 2000 Bioor-
Suitable acids include hydrofluoric acid, hydrochloric 
acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric 
acid, phosphoric acid, carbonic acid, boric acid, selenious 
acid, hydrogen sulfide, phosphomolybdic acid, phosphorous 
acid, sulfurous acid, citric acid, maleic acid, D-malic acid, 
L-lactic acid, D-lactic acid, DL-lactic acid, oxalic acid, 
methanesulfonic acid, valerie acid, oleic acid, lauric acid, 
para-toluenesulfonic acid, 1-naphthalensulfonic acid, 
2-naphthalensulfonic acid, phthalic acid, tartaric acid, 
L-malic acid, DL-malic acid, malonic acid, succinic acid, 
fumaric acid, glycolic acid, thioglycolic acid, glycine, sar-
cocine, sulfonic acid, nicotinic acid, picolinic acid, isonico-
tinic acid, benzoic acid and substituted benzoic acid where 
benzene ring bears one or more substituents. 
20 ganic & Med. Chern Letters 10: 2075-2078) each of which 
is incorporated in their entirety herein by reference. 
The invention relates to the ability of the a-methylene-
y-butyrolactone moiety in sesquiterpene lactones to be struc-
turally modified by, for example, Michael addition with 
25 amines or thiols. Modification of the parthenolide (1) mol-
ecule by this methodology using primary and/or secondary 
amines to form water-soluble amino derivatives, affords 
amine adducts that can easily be obtained as different 
inorganic or organic salts to further increase water solubility. 
Pharmaceutically acceptable salts may be obtained using 
standard procedures well known in the art, for example, by 
reacting a sufficiently basic compound such as an amine with 
a suitable acid affording a physiologically acceptable anion. 
Alkali metal (for example, sodium, potassium or lithium) or 
alkaline earth metal (for example, calcium) salts of carbox-
ylic acids can also be made. 
30 Thus, a novel class of more water-soluble parthenolide 
analogs is described. When compounds in this class were 
evaluated for antileukemic activity, it was found that these 
compounds were either equipotent as, or more potent than 
the parent compound, parthenolide. More importantly, these 
35 novel analogs showed greater cytotoxicity towards leukemia 
cells than towards normal cells. Thus, the present invention 
provides a new class of parthenolide derivatives with potent 
and selective anticancer activities. The term "prodrug" or "prodrugs" is used in its ordinary 
meaning in the art and means a compound of the invention 
that has its charged moieties masked or protected by another 
moiety that is designed to be cleaved under particular 
physiological conditions, leaving the deprotected or 
unmasked compound of the invention. The use of masking 
agents is common and well-known in the art and, in par-
ticular, masking phosphate or phosphonate groups. All such 45 
masking agents are suitable and can be used with the 
compounds of the invention. Various agents such as acyloxy 
alkyl esters are described by Srivasta et a!., (1984 Bioor-
ganic Chemistry 12, 118-12), and by Freeman eta!. (1997 
Progress in Medicinal Chemistry 34:112-147) which are 50 
each incorporated in their entirety herein by reference; and 
3-phthalidyl phosphonate esters are described by Dang Q., et 
a!., (1999 Bioorganic & Med. Chern Letters, 9:1505-1510), 
which is incorporated in its entirety herein by reference. For 
example, and not by way of limitation, Srivasta et a!. also 55 
describe acetoxymethyl, isobutryloxymethyl, and piv-
aloxymethyl as masking agents. Other suitable masking 
groups comprising pivaloxyalkyl, e.g., pivaloxymethyl, or a 
pivaloyloxy group as described by Farquhar D. eta!., (1995 
In accordance with the present invention, there are pro-
40 vided compounds of formula (I): 
J. Med. Chern., 38:488-495) which is incorporated in its 60 
entirety herein by reference. Still other masking or protect-
ing agents are described in U.S. Pat. Nos. 4,816,570 and 
4,968, 788 both of which are incorporated in their entirety 
herein by reference. Lipid prodrugs are also suitable for use 
with the compounds of the invention. By non-limiting 65 
example, certain lipid prodrugs are described in Hostetler et 
a!., (1997 Biochem. Pharm. 53:1815-1822), andHostetleret 
(I) 
z 
wherein: 
X 1 , X2 and X3 are heteroatoms; 
R4 , R5 , R6 , R7 , R8 , R9 and R10 are independently selected 
from H, halo, ---OH, -N02 , ---CN and optionally substi-
tuted aliphatic, cycloalkyl, heterocycloalkyl, aryl or het-
eroaryl; and 
Z is optionally substituted C1_8 straight-chained or 
branched aliphatic, optionally containing 1 or more double 
or triple bonds, wherein one or more carbons are optionally 
replaced by R * wherein R * is optionally substituted 
cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino 
acid residue, H, ---CN, -C(O)-, -C(O)C(O)-, ---C(O) 
NR1-, -C(O)NR1NR2-, ---C(O)O-, ---OC(O)-, 
-NR1C02-, ---0-, -NR
1C(O)NR2-, ---OC(O) 
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NR1-, -NR1NR2-, -NR1C(O)-, -S-, -SO-, 
-S02-, -NR
1
-, -S02NR
1
-, -NR1R2, or 
-NR 1 S02-, wherein R 
1 and R 2 are independently selected 
from H and optionally substituted aliphatic, cycloalkyl, 
heterocycloalkyl, aryl or heteroaryl; or where R * is NR1R2, 5 
R1 and R2 optionally together with the nitrogen atom form 
an optionally substituted 5-12 membered ring, said ring 
optionally comprising 1 or more heteroatoms and/or a group 
selected from --CO-, -SO-, -S02- and -PO-; or 
a pharmaceutically acceptable salt, ester or prodrug 10 
thereof. 
10 
din-1-yl, pyrrolidin-1-yl, piperidin-1-yl, homopiperidyn-1-
yl and heptamethyleneimin-1-yl. 
According to a further embodiment of the invention, Z is 
-(CH2)m-S(O)n-R
1 where m is an integer from 0 to 4, n 
is an integer from 0 to 2, where preferably, R5 , R6 , R7 , R9 , 
and RIO are H; and R4 and R8 are each ---CH3 . In one 
particular embodiment, m is 1. In another embodiment n is 
0. In other embodiments, R1 is independently selected from 
hydrogen, ---CN, optionally substituted C1 -C4 alkyl or aryl. 
In particular embodiments, R1 is selected from -C6H5 , 
---CH2CH(C02H)(NH2), and -CH2C02H. 
Exemplary compounds of the present invention include: 
11 S, 11, 13-Dihydro, 13-dimethylaminoparthenolide 
(DMAPT); 
Presently preferred compounds include compounds of 
formula (I) wherein R5 , R6 , R7 , R9 and RIO are indepen-
dently selected from H, halo, ---OH, -N02, ---CN, ---CH3 , 
-CF3 , ---CH2CH3 , ---CH2CF3 , ---CH2Cl, ---CH20H, 
15 11 S,11, 13-Dihydro,13-diethylaminoparthenolide; 
-CH2CH20H and ---CH2NH2. Further preferred embodi-
ments include compounds where R5 , R6 , R7 , R9 and RIO are 
each H. 
Other preferred embodiments of the present invention 
include compounds where R4 and R8 are independently 
selected from optionally substituted C1-C4 alkyl. In one 
preferred embodiment, R4 is -CH3 , and in another, R4 and 
R8 are each -CH3 . 
In one embodiment X1 , X2 and X3 are heteroatoms inde-
pendently selected from 0, N and S, and in one particular 
embodiment, X1 , X2 and X3 are each 0. 
According to one embodiment, it is preferred that where 
R5 , R6 , R7 , R9 and RIO are H, R4 and R8 are each -CH3 , and 
X1 , X2 and X3 are each 0; Z is not =CH2. 
11 S, 11, 13-Dihydro, 13-(tert-butylamino )parthenolide; 
11 S, 11, 13-Dihydro, 13-(pyrrolidin-1-yl)parthenolide; 
11 S, 11, 13-Dihydro, 13-(piperidin-1-yl)parthenolide (PIPT); 
11 S, 11, 13-Dihydro, 13-(morpholin-1-yl)parthenolide; 
20 11 S,11, 13-Dihydro,13-( 4-methylpiperidin-1-yl)partheno-
lide (4MEPT); 
11 S,11, 13-Dihydro,13-( 4-methylpiperazin-1-yl)partheno-
lide; 
11 S, 11, 13-Dihydro, 13 -(homopiperidin -1-yl )parthenolide; 
25 11 S, 11, 13-Dihydro, 13-(heptamethyleneimin-1-yl)partheno-
lide; 
11 S, 11, 13-Dihydro, 13-( azetidin-1-yl)parthenolide; 
11 S, 11, 13-Dihydro, 13 -methy lbuty I aminoparthenolide; 
11S,11,13-Dihydro,13-methyl pentyl aminoparthenolide; 
30 11 S,11, 13-Dihydro,13-ethylaminoparthenolide; 
11 S, 11, 13-Dihydro, 13-methylaminoparthenolide; According to a further embodiment of the invention, Z is 
-(CH2)m -NR 
1 R 2 where m is an integer from 0 to 4, where 
preferably, R5 , R6 , R7 , R9 , and RIO are H; and R4 and R8 are 
each ---CH3 . In one particular embodiment, m is 1. In other 
embodiments, R1 and R2 are independently selected from 35 
hydrogen, ---CN or optionally substituted C1 -C4 alkyl. In 
particular embodiments, R1 and R2 are independently 
selected from -N02, ---CN, ---CH3 , -CF3 , -CH2CH3 , 
-CH2CF3 , -CH2Cl, -CH20H, -CH2CH20H and 
11 S, 11, 13-Dihydro, 13-cyclopropylaminoparthenolide; 
11 S, 11, 13-Dihydro, 13-propargylaminoparthenolide; 
11 S, 11, 13-Dihydro, 13-(N -benzyl-N -ethylamine )partheno-
lide; 
11 S, 11, 13-Dihydro, 13-(N -prolyl)parthenolide; 
11 S, 11, 13-Dihydro, 13-(S-thiophenolyl)parthenolide; 
11 S, 11, 13-Dihydro, 13-(N,N -diethanolamine )parthenolide 
11 S, 11, 13-Dihydro, 13-(thiomorpholin-4-yl)parthenolide; 
-CH2NH2. 
In yet a further embodiment, R 1 and R 2 together with N 
form an optionally substituted ring. The ring is a monocy-
clic, bicyclic or tricyclic aliphatic or aryl ring system, where 
the ring system is optionally substituted and optionally 
comprises one or more heteroatoms or a group selected from 
-CO-, -SO-, -S02- and -PO-. In one particular 
embodiment, R1 andR2 are---CH2(CH2)nCH2Y-, whereY 
40 11 S,11, 13-Dihydro,13-( 4-hydroxypiperidin-1-yl)partheno-
lide; 
11 S, 11, 13-Dihydro, 13-(1-methylhomopiperizin-4-yl)par-
thenolide; 
11 S, 11, 13-Dihydro, 13-(S-mercaptoacetyl)parthenolide; 
45 11 S,11, 13-Dihydro,13-( 4-(2'-hydroxyethyl)piperidin-1-yl) 
parthenolide; 
11 S, 11, 13-Dihydro, 13-(piperazin-1-yl-4-carboxaldehyde) 
parthenolide; 
11 S,11, 13-Dihydro,13-( 4-benzylpiperidin-1-yl)partheno-
lide; 
11 S,11, 13-Dihydro,13-(piperidin-1-yl-4-carboxylic acid) 
parthenolide; 
11 S, 11, 13-Dihydro, 13-( azetidin-1-yl-3-carboxylic acid)par-
thenolide; 
is a heteroatom or a group selected from --CO-, -SO-, 
-S02- and -PO-; n is an integer 0 to 5; and together 
with N form an optionally substituted ring, which may be 50 
additionally fused to a cycloalkyl or aryl group to form a 
bicyclic or tricyclic ring system, where the system is option-
ally substituted and optionally comprises one or more het-
eroatoms. Alternatively, R1 and R2 are -(CH2)a-Y-
(CH2)6-, where Y is a heteroatom or a group selected from 
-CO-, -SO-, -S02- and -PO-; a is an integer 0 
55 11 S,11, 13-Dihydro,13-(S-cysteinyl)parthenolide; 
11 S,11, 13-Dihydro,13-( 4-(piperidin-1 '-yl)piperidin-1-yl)) 
parthenolide; and to 5; b is an integer 0 to 5; where the sum of a and b is 0 to 
5; and together with N form an optionally substituted ring, 
the ring being optionally fused to a cycloalkyl or aryl group 
to form a bicyclic or tricyclic ring system, where the system 
is optionally substituted and optionally comprises one or 
more heteroatoms. 
Examples of ring systems include an optionally substi-
tuted uracil ring or a derivative thereof. Other examples 
include optionally substitute pyrrole, imidazole, purine and 
pyrazole and derivative thereof. Examples of fused ring 
systems include optionally substituted aziridin-1-yl, azeti-
11 S, 11, 13-Dihydro, 13-diallylaminoparthenolide. 
Those of skill in the art will recognize that the invention 
60 comprises compounds that may contain one or more chiral 
centers on, for example, the parthenolide C-11 and thus can 
exist as racemic mixtures as pure diastereomers, or as pure 
enantiomers. For many applications, it is preferred to carry 
out stereoselective synthesis and/or to subject the reaction 
65 product to appropriate purification steps so as to produce 
substantially stereochemically pure or optically pure mate-
rials. Suitable stereoselective synthetic procedures for pro-
US 9,447,112 B2 
11 
ducing stereochemically pure or optically pure materials are 
well known in the art, as are procedures for resolving 
racemic mixtures into their optically pure enantiomers. 
The present invention further provides for compounds 
having formula (I), or a pharmaceutically acceptable salt 
thereof, wherein Z is a group that is converted to =CH2 
under physiological conditions during or after administra-
tion to a mammalian patient, thereby yielding a methylene 
group. In particular embodiments X1 , X2 and X3 are 0; R5 , 
R6, R7, R9 , and RIO are H; R4 and R8 are ---CH3 ; and Z is 
10 
optionally substituted C1 _8 straight-chained or branched ali-
phatic, optionally containing 1 or more double or triple 
bonds, wherein one or more carbons are optionally replaced 
by R * wherein R * is optionally substituted cycloalkyl, 
15 
heterocycloalkyl, aryl or heteroaryl; an amino acid residue, 
H, ---CN, -C(O)-, ---C(O)C(O)-, ---C(O)NR1-, 
-C(O)NR1NR2-, -C(O)O-, -OC(O)-, 
-NR1C02-, ---0-, -NR
1C(O)NR2-, ---OC(O) 
NR1-, -NR1NR2-, -NR1C(O)-, -S-, -SO-, 20 
-S02-, -NR
1
-, -S02 NR
1
-, -NR1R2 , or 
-NR 1 S02-, wherein R 
1 and R 2 are independently selected 
from H and optionally substituted aliphatic, cycloalkyl, 
heterocycloalkyl, aryl or heteroaryl. In preferred embodi-
ments Z is -CH2N(CH3 ) 2 , -CH2N(H)(C(CH3 ) 3 ), 25 
-CH2 N(CH2 CH3 ) 2 , -CH2N(CH2CH=CH2 ) 2 , ---CH2 -
azetidine, -CH2 -pyrrolidine, ---CH2 -piperidine, ---CH2 -
homopiperidine, ---CH2 -heptamethyleneimine, ---CH2 -4-
methylpiperidine, ---CH2 -morpholine, -CH2 -pyrrolidine, 
-CH2 -proline, ---CH2 -thiophenol, ---CH2 -diethanolamine, 
30 
-CH2 -hydroxypiperidine, ---CH2 -methylhomopiperazine, 
-CH2 -thiomorpholine, -CH2 -mercaptoacetic acid, 
-CH2 -benzylpiperidine, ---CH2 -piperidine-4-carboxylic 
acid, ---CH2 -azetidine-3-carboxylic acid, ---CH2 -piperidi- 35 
nylpiperidine, or ---CH2 -cysteine. 
The present invention further provides for compounds 
having formula (I), or a pharmaceutically acceptable salt 
thereof, wherein Z is CH2N(CH3 ) 2 which under physiologi-
cal conditions during or after administration to a mammalian 40 
patient, undergoes mono- or di-demethylation; conversion to 
=CH2 , or cysteine or protein conjugation. In particular 
embodiments, X1, x2 and x3 are 0; Rs, R6, R7, ~'and RIO 
are H; R4 and R8 are -CH3 ; 
The present invention further provides compounds 45 
wherein the parthenolide based derivatives of formula (I) 
form dimers or duplexes with another molecule of formula 
(I) or with basic nitrogen-containing synergistic anticancer 
drug molecules such as 5-fluorouracil, cytarabine, mytomy-
cin C, Doxorubicin and Daunorubicin. Accordingly, the 50 
present invention provides compounds of the general for-
mula (II): 
(II) 55 
L-W 
where Lis a linker, as defined above, and W is a molecule 
with anti-cancer growth activity. Where W is another par-
60 
65 
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thenolide derivative of formula (I), the present invention 
provides compounds of formula (III): 
(III) 
where R'4 , R'5 , R'6, R'7, R'8 , R'9 , R'IO, X'u X'2 and X'3 are 
independently as defined above for their counterparts, R6, 
R7, R8 , R9 , RIO, Xu X2 and X3 ; and Lis a linker, as defined 
above. Preferred linkers include optionally substituted alkyl 
and amine groups. In one particular embodiment, L is 
---CH2N(R)CH2-, where R is as defined above. Included 
are pharmaceutically acceptable salts formed with inorganic 
and/or organic acids, as defined above for compounds of 
formula (I). 
In accordance with another embodiment of the invention, 
the methods for the preparation of the amino analogs 
described in this invention are disclosed in Schemes I and II. 
13 
13 
Scheme I 
solvent, base 
temperature 
Scheme II 
R3NH2 
solvent, 
base 
temperature 
2 
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0 
In the above scheme, the solvent is selected from a low alkyl 
alcohol, such as methanol, ethanol, propanol, isopropanol, 
n-butanol, tert-butanol, and chloroform, methylene chloride, 
benzene, toluene, tetrahydrofuran, dioxane, 1,2-dimethoxy-
ethane, pyridine, carbon tetrachloride, diethyl ether, tert-
butyl methyl ether and/or the mixture of two or more of the 
solvents listed above. The base is selected from a low 
trialkylamine, such as trimethylamine, triethylamine, tripro-
2 
14 
pylamine, and tributylamine, and pyridine, 2-, 3-, and 4-pi-
colines, 2-, 3-, and 4-dimethylaminopyridines. The tempera-
ture is selected from -20° C. to 130° C. The reaction time 
required to effect the desired coupling reaction can vary 
widely, typically falling in the range of 30 min to 24 hours. 
Purification can be achieved by a variety of techniques, such 
as, liquid chromatography through neutral or basic silica gel, 
bonded silica gel phases such as octadecylsilica, octylsilica 
and the like, cellulose or alumina with the solvent such as, 
10 for example, the mixture of chloroform and methanol or 
ethanol, the mixture of methylene chloride and methanol or 
ethanol, the mixture of hexane and acetone or acetonitrile or 
methanol or ethanol or isopropanol, the mixture of diethyl 
15 
ether and acetone or acetonitrile or methanol or ethanol or 
isopropanol; and recrystallization using normal organic sol-
vent or solvent mixture, such as methanol, ethanol, propa-
nol, isopropanol, tert-butanol, acetonitrile, diethyl ether, 
chloroform, methylene chloride and the mixture of two or 
20 
more solvents listed above. The purity of the invention 
compounds prepared is assessed by mass spectrometry, 
nuclear magnetic resonance spectrometry (NMR) and 
elemental combustion analysis. 
Furthermore, in accordance with still another embodiment 
of the present invention, the methods for the preparation of 
the invention salts are disclosed in Schemes III and IV. 
Scheme III ---
AcidHX 
solvent 
temperature 
"{y 
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In these schemes, HX is selected from hydrochloride, 
hydrobromide, hydroiodide, perchlorate, sulfate, hemisul-
fate, mesylate, toluenesulfonate, benzenesulfonate, succi-
nate, hemisuccinate, fumarate, tartarate, ascorbate, acetate, 
hemifumarate, maleate, citrate, oxalate, malonate, malic, 
propionate and benzoate; YE> is selected from halide (fluo-
ride, chloride, bromide, iodide), methylsulfonate, toluene-
sulfonate, benzenesulfonate and sulfate; and the solvent is 
selected from a low alkyl alcohol, such as diethyl ether, 
methanol, ethanol, propanol, isopropanol, n-butanol, tert-
DUPLEX ANALOG 
16 
butanol, and chloroform, methylene chloride, benzene, tolu-
ene, tetrahydrofuran, dioxane, 1 ,2-dimethoxyethane, pyri-
dine, carbon tetrachloride, tert-butyl methyl ether, acetone 
and/or the mixture of two or more of the solvents listed 
above. The temperature is selected from -20° C. to 50° C. 
Purification can be achieved by recrystallization using nor-
mal organic solvent or solvent mixture, such as methanol, 
ethanol, acetone, propanol, isopropanol, t-butanol, acetoni-
trile, diethyl ether, chloroform, methylene chloride and the 
mixture of two or more solvents listed above. 
Scheme IV 
0 
H = H 
,,,H Vll/ e 
··• H N X 
..... ,/ \ 
R3 
0 
7 
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The present invention further provides analogues of com-
pounds of formula (I), Examples are described below and 
include costunolide, dehydrocostuslactone, alantolactone, 
isoalantolactone, amino-3-oxo-isoalantolactone, helenalin, 
11, 13 -dihydrohelenalin, aminocyanaropicrin, aminodesa-
cylcyanaropicrin, ( + )-aminoreyonosin, aminosantamarin, 
aminosoulangianolide and aminoisotelekin, In addition, the 
present invention provides compounds of the analogues 
below, amino-3-oxo-isoalantolactone, aminocyanaropicrin, 
aminodesacylcyanaropicrin, ( + )-aminoreyonosin, amin- 10 
osantamarin, aminosoulangianolide and aminoisotelekin 
wherein (---CH2-NR1R2 ) is replaced by Z, where Z is as 
defined herein, 
0 
Dehydrocostuslactone 
Helena! in 
Costunolide 
Alantolactone 
Isoalantolactone 
11 ,13-Dihydrohelenalin 
Arninocynaropicrins 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
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-continued 
OH 
( + )-Arninoreynosins 
OH 
0 
Aminosantarnarins 
Aminosoulangianolides 
0 
Amino-3-oxo-isoalantolactones 
Arninoisotelekins 
The invention relates to the ability of the a-methylene-
y-butyrolactone moiety in all the above-mentioned sesquit-
erpene lactones to be structurally modified by, for example, 
Michael addition with the following chemical entities to 
form more water-soluble derivatives than the corresponding 
Aminodesacylcynaropicrins 
65 parent sesquiterpene, and with improved properties condu-
cive for drug development, such as, chemical stability, 
reduced toxicity and oral bioavailability, 
US 9,447,112 B2 
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The present invention further provides compounds of the 
parthenolide-analog dehydrocostuslactone based derivatives 
of formula (IV): 
(IV) 
Rs 
z 
Presently preferred compounds include compounds of 
formula (IV) wherein R3 , R5 , R6 , R9 and RIO are indepen-
dently selected from H, halo, ---OH, -N02, ---CN, ---CH3 , 
-CF3 , ---CH2CH3 , ---CH2CF3 , ---CH2Cl, ---CH20H, 
-CH2CH20H and ---CH2NH2. Further preferred embodi-
ments include compounds where R3 , R5 , R6 , R9 and RIO are 
each H. 
Other preferred embodiments of the present invention 
include compounds where R4 and R8 are independently 
selected from optionally substituted C1-C4 alkyl. In one 
preferred embodiment, R4 and R8 are each =CH2. 
In one embodiment X 1 and X2 are heteroatoms indepen-
dently selected from 0, N and S, and in one particular 
embodiment, X 1 and X2 are each 0. 
According to a further embodiment of the invention, Z is 
-(CH2)m -NR 
1 R 2 where m is an integer from 0 to 4, where 
preferably, R5 , R6 , R7 , ~ and RIO are H; and R4 and R8 are 
each ---CH3 . In one particular embodiment, m is 1. In other 
embodiments, R1 and R2 are independently selected from 
hydrogen, ---CN or optionally substituted C1 -C4 alkyl. In 
particular embodiments, R1 and R2 are independently 
selected from -N02, ---CN, ---CH3 , -CF3 , -CH2CH3 , 
-CH2CF3 , -CH2Cl, -CH20H, -CH2CH20H and 
-CH2NH2. 
In yet a further embodiment, R 1 and R 2 together with N 
form an optionally substituted ring. The ring is a monocy-
clic, bicyclic or tricyclic aliphatic or aryl ring system, where 
the ring system is optionally substituted and optionally 
comprises one or more heteroatoms or a group selected from 
-CO-, -SO-, -S02- and -PO-. In one particular 
embodiment, R1 andR2 are---CH2(CH2)nCH2Y-, whereY 
20 
pyrazole and derivative thereof. Examples of fused ring 
systems include optionally substituted aziridin-1-yl, azeti-
din-1-yl, pyrrolidin-1-yl, piperidin-1-yl, homopiperidyn-1-
yl and heptamethyleneimin-1-yl. 
With respect to formulas (I) and (IV), in other embodi-
ments, Z is hydroxylamine, a hydroxyalkylamino com-
pound, a thioalkylamino compound, a diaminoalkane. 
Examples include ethylenediamine, piperazine, triaminoal-
kanes, polyamines, polylysine, putrescine, spermine, sper-
10 midine, aminoguanidines and agmatine. In other embodi-
ments, Z is an amino acid. For example glycine, serine, 
hydroxyproline, ~-alanine, cysteine, homocysteine, argi-
nine, lysine, glutamic acid, ornithine, aspartic acid, y-amin-
obutyric acid, or taurine. In other embodiments, Z is an 
15 amino sugar; for example glucosamine. In other embodi-
ments, Z is a polyoxyethylene glycol of various molecular 
weights, each of which terminate in an amino functionality 
that will form an adduct with the appropriate sesquiterpene. 
Modification of the sesquiterpene molecules by these 
20 methodologies, affords adducts that can easily be obtained as 
different inorganic or organic salts to further increase water 
solubility. 
The compounds described herein are useful for treating 
cancer. Cancers treatable by the present therapy include the 
25 solid and hematological tumors, such as prostate cancer, 
ovarian cancer, breast cancer, brain cancer and hepatic 
cancer, comprising administering to a mammal afflicted with 
said cancer an amount of parthenolide derivative effective to 
inhibit the viability of cancer cells of said mammal. The 
30 parthenolide derivative may be administered as primary 
therapy, or as adjunct therapy, either following local inter-
vention (surgery, radiation, local chemotherapy) or in con-
junction with at least one other chemotherapeutic agent 
discussed hereinabove, as well as the solid tumors disclosed 
35 in U.S. Pat. No. 5,514,555. Hematological cancers, such as 
the leukemias are disclosed in the Mayo Clinic Family 
Health Book, D. E. Larson, ed., William Morrow, N.Y. 
(1990) and include CLL, ALL, CML and the like. Com-
pounds of the present invention may be used in bone marrow 
40 transplant procedure to treat bone marrow prior to reintro-
duction to the patient. In addition, the compounds of the 
present invention may be used as chemotherapy sensitizers 
or radiation therapy sensitizers. Accordingly, a patient, or 
cells, or tissues, derived from a cancer patient, are pre-
45 treated with the compounds prior to standard chemotherapy 
or radiation therapy. The present invention contemplates that 
parthenolide may also be used in such methods. 
Within another aspect of the present invention, methods 
are provided for inhibiting angiogenesis in patients with 
50 non-tumorigenic, angiogenesis-dependent diseases, com-
prising administering a therapeutically effective amount of a 
composition comprising parthenolide derivative to a patient 
with a non-tumorigenic angiogenesis-dependent disease, 
such that the formation of new blood vessels is inhibited. 
is a heteroatom or a group selected from --CO-, -SO-, 
-S02- and -PO-; n is an integer 0 to 5; and together 
with N form an optionally substituted ring, which may be 
additionally fused to a cycloalkyl or aryl group to form a 
bicyclic or tricyclic ring system, where the system is option-
ally substituted and optionally comprises one or more het- 55 
eroatoms. Alternatively, R1 and R2 are -(CH2)a-Y-
(CH2)6-, where Y is a heteroatom or a group selected from 
-CO-, -SO-, -S02- and -PO-; a is an integer 0 
Within other aspects, methods are provided for inhibit 
reactive proliferation of endothelial cells or capillary for-
mation in non-tumorigenic, angiogenesis-dependent dis-
eases, such that the blood vessel is effectively occluded. 
to 5; b is an integer 0 to 5; where the sum of a and b is 0 to 
5; and together with N form an optionally substituted ring, 60 
the ring being optionally fused to a cycloalkyl or aryl group 
to form a bicyclic or tricyclic ring system, where the system 
is optionally substituted and optionally comprises one or 
more heteroatoms. 
Examples of ring systems include an optionally substi- 65 
tuted uracil ring or a derivative thereof. Other examples 
include optionally substitute pyrrole, imidazole, purine and 
Within one embodiment, the anti-angiogenic composition 
comprising parthenolide derivative is delivered to a blood 
vessel which is actively proliferating and nourishing a 
tumor. 
In addition to tumors, numerous other non-tumorigenic 
angiogenesis-dependent diseases, which are characterized 
by the abnormal growth of blood vessels, may also be 
treated with the anti-angiogenic parthenolide derivative 
compositions, or anti-angiogenic factors of the present 
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or its analogs may be administered as the pure chemicals, as 
by inhalation of a fine powder via an insufllator, it is 
preferable to present the active ingredient as a pharmaceu-
tical formulation. The invention thus further provides a 
pharmaceutical formulation comprising parthenolide deriva-
tive or an analog thereof, together with one or more phar-
maceutically acceptable carriers therefor and, optionally, 
other therapeutic and/or prophylactic ingredients. The car-
rier(s) must be 'acceptable' in the sense of being compatible 
invention. Anti-angiogenic parthenolide derivative compo-
sitions of the present invention can block the stimulatory 
effects of angiogenesis promoters, reducing endothelial cell 
division, decreasing endothelial cell migration, and impair-
ing the activity of the proteolytic enzymes secreted by the 
endothelium. Representative examples of such non-tumori-
genic angiogenesis-dependent diseases include corneal neo-
vascularization, hypertrophic scars and keloids, proliferative 
diabetic retinopathy, arteriovenous malformations, athero-
sclerotic plaques, delayed wound healing, hemophilic joints, 
nonunion fractures, Osler-Weber syndrome, psoriasis, pyo-
genic granuloma, scleroderma, trachoma, menorrhagia, ret-
rolental fibroplasia and vascular adhesions. The pathology 
and treatment of these conditions is disclosed in detail in 
published PCT application PCT/CA94/00373 (WO 
95/03036), at pages 26-36. Topical or directed local admin-
istration of the present compositions is often the preferred 
mode of administration of therapeutically effective amounts 
10 with the other ingredients of the formulation and not del-
eterious to the recipient thereof, such as a human patient or 
domestic animal. 
Pharmaceutical formulations include those suitable for 
oral or parenteral (including intramuscular, subcutaneous 
of parthenolide derivative, i.e., in depot or other controlled 
release forms. 
15 and intravenous) administration. Forms suitable for paren-
teral administration also include forms suitable for admin-
istration by inhalation or insufllation or for nasal, or topical 
(including buccal, rectal, vaginal and sublingual) adminis-
tration. The formulations may, where appropriate, be con-
Anti-angiogenic compositions of the present invention 
may also be utilized in a variety of other manners. For 
example, they may be incorporated into surgical sutures in 
order to prevent stitch granulomas, implanted in the uterus 
20 veniently presented in discrete unit dosage forms and may 
be prepared by any of the methods well known in the art of 
pharmacy. Such methods include the step of bringing into 
association the active compound with liquid carriers, solid 
matrices, semi-solid carriers, finely divided solid carriers or 
25 combinations thereof, and then, if necessary, shaping the 
product into the desired delivery system. 
(in the same manner as an IUD) for the treatment of 
menorrhagia or as a form of female birth control, adminis-
tered as either a peritoneal lavage fluid or for peritoneal 
implantation in the treatment of endometriosis, attached to a 
monoclonal antibody directed against activated endothelial 
cells as a form of systemic chemotherapy, or utilized in 30 
diagnostic imaging when attached to a radioactively labelled 
monoclonal antibody which recognizes active endothelial 
cells. The magnitude of a prophylactic or therapeutic dose of 
parthenolide derivative, an analog thereof or a combination 
thereof, in the acute or chronic management of cancer, i.e., 35 
prostate or breast cancer, will vary with the stage of the 
cancer, such as the solid tumor to be treated, the chemo-
therapeutic agent(s) or other anti-cancer therapy used, and 
the route of administration. The dose, and perhaps the dose 
frequency, will also vary according to the age, body weight, 40 
and response of the individual patient. In general, the total 
daily dose range for parthenolide derivative and its analogs, 
for the conditions described herein, is from about 0.5 mg to 
about 2500 mg, in single or divided doses. Preferably, a 
daily dose range should be about 1 mg to about 100 mg, in 45 
single or divided doses, most preferably about 5-50 mg per 
day. In managing the patient, the therapy should be initiated 
at a lower dose and increased depending on the patient's 
global response. It is further recommended that infants, 
children, patients over 65 years, and those with impaired 50 
renal or hepatic function initially receive lower doses, and 
that they be titrated based on global response and blood 
level. It may be necessary to use dosages outside these 
ranges in some cases. Further, it is noted that the clinician or 
treating physician will know how and when to interrupt, 55 
adjust or terminate therapy in conjunction with individual 
patient response. The terms "an effective amount" or "an 
effective sensitizing amount" are encompassed by the 
above-described dosage amounts and dose frequency sched-
ule. 60 
Pharmaceutical formulations suitable for oral administra-
tion may be presented as discrete unit dosage forms such as 
hard or soft gelatin capsules, cachets or tablets each con-
taining a predetermined amount of the active ingredient; as 
a powder or as granules; as a solution, a suspension or as an 
emulsion; or in a chewable base such as a synthetic resin or 
chicle for ingestion of the agent from a chewing gum. The 
active ingredient may also be presented as a bolus, electuary 
or paste. Tablets and capsules for oral administration may 
contain conventional excipients such as binding agents, 
fillers, lubricants, disintegrants, or wetting agents. The tab-
lets may be coated according to methods well known in the 
art, i.e., with enteric coatings. 
Oral liquid preparations may be in the form of, for 
example, aqueous or oily suspensions, solutions, emulsions, 
syrups or elixirs, or may be presented as a dry product for 
constitution with water or other suitable vehicle before use. 
Such liquid preparations may contain conventional additives 
such as suspending agents, emulsifying agents, non-aqueous 
vehicles (which may include edible oils), or preservatives. 
The compounds according to the invention may also be 
formulated for parenteral administration (e.g., by injection, 
for example, bolus injection or continuous infusion) and 
may be presented in unit dose form in ampules, pre-filled 
syringes, small volume infusion containers or in multi-dose 
containers with an added preservative. The compositions 
may take such forms as suspensions, solutions, or emulsions 
in oily or aqueous vehicles, and may contain formulatory 
agents such as suspending, stabilizing and/or dispersing 
agents. Alternatively, the active ingredient may be in powder 
form, obtained by aseptic isolation of sterile solid or by 
lyophilization from solution, for constitution with a suitable 
vehicle, e.g., sterile, pyrogen-free water, before use. 
For topical administration to the epidermis, the com-
pounds may be formulated as ointments, creams or lotions, 
or as the active ingredient of a transdermal patch. Suitable 
transdermal delivery systems are disclosed, for example, in 
A. Fisher eta!. (U.S. Pat. No. 4,788,603), orR. Bawa eta!. 
Any suitable route of administration may be employed for 
providing the patient with an effective dosage of partheno-
lide derivative (e.g., oral, sublingual, rectal, intravenous, 
epidural, intrethecal, subcutaneous, transcutaneous, intra-
muscular, intraperitoneal, intracutaneous, inhalation, trans-
dermal, nasal spray, nasal gel or drop, and the like). While 
it is possible that, for use in therapy, parthenolide derivative 
65 (U.S. Pat. Nos. 4,931,279; 4,668,506 and 4,713,224). Oint-
ments and creams may, for example, be formulated with an 
aqueous or oily base with the addition of suitable thickening 
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(2 mmol), and triethylamine (1 to 2 mL) in 30 mL of 
anhydrous ethanol was stirred at a specific temperature 
ranging from ambient temperature to the temperature of the 
refluxing solvent utilized, or was left to stand in the refrig-
and/or gelling agents. Lotions may be formulated with an 
aqueous or oily base and will in general also contain one or 
more emulsifying agents, stabilizing agents, dispersing 
agents, suspending agents, thickening agents, or coloring 
agents. 
Formulations suitable for topical administration in the 
mouth include unit dosage forms such as lozenges compris-
ing active ingredient in a flavored base, usually sucrose and 
acacia or tragacanth; pastilles comprising the active ingre-
dient in an inert base such as gelatin and glycerin or sucrose 
and acacia; mucoadherent gels, and mouthwashes compris-
ing the active ingredient in a suitable liquid carrier. 
5 erator ( -20° C. to 4° C.) overnight for 24 hours. Ethanol, 
triethylamine and/or the appropriate volatile amine were 
then evaporated under vacuum in a rotary evaporator. The 
resulting residue was subjected to silica gel colunm chro-
matographic purification using chloroform-methanol or 
10 
methylene chloride-methanol mixed solvent as the mobile 
phase. NMR (Varian, 300 MHz and 400 MHz) and GC/MS 
(Agilent, 6890GC and 5973MSD) analysis methodologies 
were utilized to assure the identity and purity of the synthetic 
compounds. 
When desired, the above-described formulations can be 
adapted to give sustained release of the active ingredient 
employed, e.g., by combination with certain hydrophilic 
polymer matrices, e.g., comprising natural gels, synthetic 15 
polymer gels or mixtures thereof. The polymer matrix can be 
coated onto, or used to form, a medical prosthesis, such as 
a stent, valve, shunt, graft, or the like. 
Pharmaceutical formulations suitable for rectal adminis-
tration wherein the carrier is a solid are most preferably 20 
presented as unit dose suppositories. Suitable carriers 
include cocoa butter and other materials commonly used in 
the art, and the suppositories may be conveniently formed by 
admixture of the active compound with the softened or 
melted carrier(s) followed by chilling and shaping in molds. 25 
Formulations suitable for vaginal administration may be 
presented as pessaries, tampons, creams, gels, pastes, foams 
or sprays containing, in addition to the active ingredient, 
such carriers as are known in the art to be appropriate. 
For administration by inhalation, the compounds accord-
30 ing to the invention are conveniently delivered from an 
insufflator, nebulizer or a pressurized pack or other conve-
nient means of delivering an aerosol spray. Pressurized 
packs may comprise a suitable propellant such as dichlo-
rodifluoromethane, trichlorofluoromethane, dichlorotetra-
fluoroethane, carbon dioxide or other suitable gas. In the 35 
case of a pressurized aerosol, the dosage unit may be 
determined by providing a valve to deliver a metered 
amount. 
Alternatively, for administration by inhalation or insuf-
flation, the compounds according to the invention may take 40 
the form of a dry powder composition, for example, a 
powder mix of the compound and a suitable powder base 
such as lactose or starch. The powder composition may be 
presented in unit dosage form in, for example, capsules or 
cartridges or, e.g., gelatin or blister packs from which the 45 
powder may be administered with the aid of an inhalator or 
insufflator. 
For intra-nasal administration, the compounds of the 
invention may be administered via a liquid spray, such as via 
a plastic bottle atomizer. Typical of these are the Mistom-
eter® (Wintrop) and the Medihaler® (Riker). 50 
For topical administration to the eye, the compounds can 
be administered as drops, gels (U.S. Pat. No. 4,255,415), 
gums (see U.S. Pat. No. 4,136,177) or via a prolonged-
release ocular insert. 
The invention will now be described in greater detail by 55 
reference to the following non-limiting examples. 
EXAMPLES 
Example 1 
General Synthetic Procedure for the Preparation of 
llS,ll, 13-Dihydro, 13-Substituted 
Aminoparthenolides 
A mixture of parthenolide (Sigma P 0667, 100 mg, 0.4 
mmol), the appropriate primary amine or secondary amine 
60 
65 
Example 2 
11 S, 11, 13-Dihydro, 13-dimethy laminoparthenolide 
(DMAPT) 
Parthenolide (100 mg, 0.4 mmol), dimethylamine (2M in 
methanol, 1 mL), triethylamine (2 mL), ethanol (30 mL) 
were refluxed overnight. After colurm1 purification, 109 mg 
of pale yellow 11 S, 11, 13-dihydro, 13-dimethylaminoparthe-
nolide was obtained (Yield: 93%). Melting point: 143-144° 
C. 1H-NMR (300 MHz, CDC13 ): ll 5.22 (lH, d), 3.85 (lH, 
t), 2.75 (2H, m), 2.65 (lH, dd), 2.5-2.3 (3H, m), 2.25 (6H, 
s), 2.5-2.0 (5H, m), 1.7 (3H, s), 1.3 (3H, s), 1.3-1.15 (lH, m). 
13C-NMR (300 MHz, CDC13 ): ll176.1, 134.4, 124.8, 81.9, 
66.4, 61.3, 57.6, 47.8, 46.4, 46.1, 41.0, 36.6, 29.9, 24.0, 17.2, 
16.9. Mass Spec (GC-MS): 293 (M+) Retention time: 12.56 
minutes. Ultra-violet (Methanol): "-max at 214 nm. Infra-Red 
(Nujol): 1757.9, 1460, 1377 cm- 1 . X-ray crystallographic 
analysis using a Nonius KappaCCD diffractometer DMAPT 
(11 S, 11, 13-dihydro, 13-dimethylaminoparthenolide) has the 
S-configuration at C-11. 
Example 3 
11 S,ll, 13-Dihydro, 13-diethylaminoparthenolide 
Parthenolide (100 mg, 0.4 mmol), diethylamine (200 mg, 
2.7 mmol), triethylamine (2 mL), ethanol (30 mL) were 
refluxed overnight. After colurm1 purification, 114 mg of 
yellow 11 S, 11, 13-dihydro, 13-diethylaminoparthenolide was 
obtained (Yield: 88%). 
Example 4 
Preparation of Salts of 
11 S,ll, 13-Dihydro, 13-aminoparthenolide 
Derivatives 
The aminoparthenolide derivative was dissolved in anhy-
drous ether and to this solution was added the corresponding 
acid in ether or ethanol. The mixture was kept in the 
refrigerator (4° C.) overnight. The crystals formed was 
filtered and dried under vacuum, or submitted to further 
recrystallization, if needed. 
Example 5 
Preparation of 
11 S, 11, 13-dihydro, 13-(piperidin-1-yl)parthenolide 
hydrochloride 
liS, 11 ,13-dihydro, 13-(piperidin-1-yl)parthenolide (5 
mg) was dissolved in 2 mL of dry ether. Hydrochloride in 
US 9,447,112 B2 
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ether (1M, 0.015 mL) was added to the ether solution until 
the solution became cloudy; then more ether was added and 
the mixture was heated to obtain a clear solution. The 
mixture was left in refrigerator (4° C.) for more than 24 
hours. The white crystals that formed were filtered through 
filter paper, and dried under vacuum overnight (Yield: 18% ). 
Example 6 
Preparation of 
11 S, 11, 13-dihydro, 13-dimethylaminoparthenolide 
maleate 
10 
To 11S,11,13-dihydro,13-dimethylaminoparthenolide (30 
mg, 0.1 mmol) in anhydrous ethanol (5 mL) was added 
maleic acid (12 mg, 0.1 mmol) in 3 mL of anhydrous 15 
ethanol. The solution was shaken well and filtered through 
a regular filter paper. The clear solution was left in the 
refrigerator for a week. The white crystals formed were 
obtained by filtration, dried in a desiccator under vacuum 
26 
was added iodomethane (90 mg, 0.6 mmol) in methanol (1 
mLI). The clear solution was shaken and stored at room 
temperature. After three days, the methanol was evaporated, 
the pale yellow residue was dried in a desiccator under 
vacuum, over anhydrous CaC12 . Recrystallization from 
acetone-ether afforded pale yellow crystals (Yield: 79%). 
Example 9 
Assay for Antileukemic Activity 
For apoptosis analysis, one million primary acute myel-
ogenous leukemia (AML) cells were washed with cold PBS 
and resuspended in 200 microliters of Annexin binding 
buffer (10 mM HEPES/NaOH pH 7.4; 140 mM NaCl; 2.5 
mM CaCl2). Annexin V-FITC (Pharmingen) and 0.25 
mg/mL 7-AAD (7-aminoactinomycin D, Molecular Probes, with anhydrous CaC12 (Yield: 55%). 
Example 7 
Preparation of 
11 S, 11, 13-dihydro, 13-Dimethylaminoparthenolide 
methiodide 
20 CA) were added and the tubes were incubated at room 
temperature in the dark for 15 minutes. Cells were then 
diluted with 200 microliters of Annexin binding buffer and 
analyzed immediately by flow cytometry. Viable cells were 
identified as failing to label withAnnexin V or 7 -AAD. Cells 
25 beginning to die label with Annexin V, and as membrane 
integrity is lost, will also label with 7-AAD. For each 
parthenolide derivative, the 
To 11S,11,13-dihydro,13-dimethylaminoparthenolide (30 
mg, 0.1 mmol) in anhydrous methanol (5 mL) was added 
iodomethane (90 mg, 0.6 mmol) in methanol (1 mL). The 
clear solution was shaken and stored at room temperature. 30 
After three days, the methanol was evaporated, the pale 
yellow residue was dried in a desiccator under vacuum, over 
anhydrous CaC12 . Recrystallization from acetone-ether 
afforded pale yellow crystals (Yield: 86% ). 
percentage of viable cells was determined after 24 hours of 
culture at a 10 micromolar concentration. Data are normal-
ized to untreated control specimens. The data are in Table 1 
for aminoparthenolide derivatives and Table 2 for the salts 
of some aminoparthenolides. 
Healthy human bone marrow cells were used in the above 
Example 8 
11 S, 11, 13-dihydro, 13-( 4-Methylpiperidin-1-yl)par-
thenolide methiodide 
35 
assay to test the cytotoxicity of parthenolide. Eighty-five 
percent of the normal cells survived 10 f.LM of parthenolide. 
All the aminoparthenolides evaluated afforded results simi-
lar to parthenolide, i.e. the survival rate of healthy human 
bone marrow cells was over 85% at a concentration of 10 
To 11S,11,13-dihydro,13-(4-methylpiperidin-1-yl)parthe- 40 M 
nolide (35 mg, 0.1 mmol) in anhydrous methanol (5 mL) fl · 
TABLE 1 
Arninoparthenolides and their antileukemic activity 
Compound 
Parthenolide 
11 S,11,13-Dihydro,13-
Reactants and 
Solvent 
Sigma P0667 
Parthenolide (100 mg), 
dimethylaminoparthenolide dimethylamine 
(DMAPT) (2M in methanol, 1 mL), 
11 S,11,13-Dihydro,13-
diethylaminoparthenolide 
(DEAPT) 
11 S,11,13-Dihydro,13-
(tert-butylamino) 
parthenolide (tBAPT) 
triethylamine(2 mL ), 
ethanol (30 mL) 
Parthenolide (100 mg), 
diethylamine 
(200 mg, 2.7 mmol), 
triethylamine (2 mL), 
ethanol (30 mL) 
Parthenolide (20 mg), 
tert-butylamine 
(0.2 mL), 
triethylamine (0.4 mL), 
ethanol (5 mL) 
Reaction 
Conditions 
Not 
applicable 
(N.A.) 
Refluxing 
overnight 
Refluxing 
overnight 
Refluxing 
10 hours 
Yield Antileukemic 
(%) activity 
N.A. 10 f!M, 84% 
93 5 f!M, 31% 
10 f!M, 90% 
20 f!M, 95% 
88 10 f!M, 60% 
39 10 f!M, 20% 
us 9,447,112 B2 
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TABLE !-continued 
ArninoEarthenolides and their antileukemic activi!I 
Reactants and Reaction Yield Antileukemic 
Compound Solvent Conditions (%) activity 
11S,ll ,13-Dihydro,13- Parthenolide (30 mg), Refluxing 80 5 fJM, 23% 
(pyrrolidin-1-yl) pyrrolidine (0.2 mL), 12 hours 10 f!M, 85% 
parthenolide (PyrPT) triethylamine 20 f!M, 95% 
(0.2 mL), ethanol (5 mL) 
11S,ll ,13-Dihydro,13- Parthenolide (250 mg), Refluxing 86 2.5 fJM, 71% 
(piperidin-1-yl)parthenolide piperidine (1 mL), overnight 5fJM,91% 
(PipPT) triethylamine 
(5 mL), ethanol (100 mL) 
11S,ll ,13-Dihydro,13- Parthenolide (100 mg), Refluxing 91 5 fJM, 5% 
(morpholin-1- morpho line overnight 20 f!M, 20% 
yl)parthenolide (MorPT) (0.5 mL), 
triethylamine (2 mL ), 
ethanol (30 mL) 
11S,11 ,13-Dihydro,13-(4- Parthenolide (100 mg), Refluxing 89 10 f!M, 83% 
methylpiperidin-1- 4- overnight 
yl)parthenolide methylpiperidine 
(4MePipPT) (0.5 mL), 
triethylamine (2 mL ), 
ethanol (30 mL) 
11S,11 ,13-Dihydro,13-(4- Parthenolide (30 mg), Refluxing 74 10 f!M, 7% 
methylpiperazin-1- 4- overnight 
yl)parthenolide methylpiperazine 
(4MePizPT) (0.2 mL), 
triethylamine (1 mL), 
ethanol (20 mL) 
11S,ll ,13-Dihydro,13- Parthenolide (100 mg), Refluxing 82 10 f!M, 40% 
(homopiperidin-1- homopiperidine overnight 
yl)parthenolide (500 mg), 
(HomoPipPT) triethylamine (2 ml), 
ethanol (30 ml) 
11S,ll ,13-Dihydro,13- Parthenolide (100 mg), Refluxing 74 10 f!M, 10% 
(heptamethyleneimin-1- heptamethyleneimin overnight 
yl)parthenolide (500 mg), 
(HeptaMePipt) triethylamine (2 mL ), 
ethanol (30 mL) 
11S,ll ,13-Dihydro,13- Parthenolide (100 mg), Stirred at 93 
( azetidin-1-yl)parthenolide azetidine (100 mg), room 
(AzePT) triethylamine temperature 
(2 mLl), ethanol (20 mL) 2 days 
11S,ll ,13-Dihydro,13- Parthenolide (100 mg), Refluxing 57 
diallylaminoparthenolide diallylamine overnight 
(200 mg), 
triethylamine (2 mL ), 
ethanol (30 mL) 
11S,ll ,13-Dihydro,13- Parthenolide 25 mg Room 85% 10 f!M, 68% 
Methylbutyl amino- Methylbutylamine temperature 
parthenolide 20 mg with 
Methanol, 8 hrs stirring 
11S,ll ,13-Dihydro,13- Parthenolide 25 mg Room 88% 10 f!M, 45% 
Methyl pentyl amino Methylpentylamine temperature 
parthenolide 20 mg Methanol, 6 hrs with 
stirring 
11S,ll ,13-Dihydro,13- Parthenolide 25 mg Room 90% 10 f!M, 2% 
ethylamino Ethylamine 90 mg temperature 
parthenolide Methanol, 5 hrs with 
stirring 
11S,ll ,13-Dihydro,13- Parthenolide 25 mg, Room 93% 10f!M,4% 
methylamino parthenolide 2M Methylamine in temperature 
methanol (1 ml), with 
Methanol, 5 hrs stirring 
11S,ll ,13-Dihydro,13- Parthenolide 25 mg Room 90% 10 f!M, -6% 
cyclopropylamino Cyclopropylamine temperature 
parthenolide 20 mg Methanol, 6 hrs with 
stirring 
11S,ll ,13-Dihydro,13- Parthenolide 25 mg Room 82% 10 f!M, 7% 
propargylamino Propargylamine temperature 
parthenolide 20 mg Methanol, 6 hrs with 
stirring 
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29 30 
TABLE 2 
Arninoparthenolide salts and their antileukemic activity 
Compound 
11S,ll ,13-Dihydro,13-
dimethylaminoparthenolide 
hydrochloride 
11S,ll ,13-Dihydro,13-
(pyrrolidin-1-
yl)parthenolide 
hydrochloride 
11S,ll ,13-Dihydro,13-
(piperidin-1-
yl)parthenolide 
hydrochloride 
11S,ll ,13-Dihydro,13-
(4-methylpiperidin-1-
yl)parthenolide 
hydrochloride 
11S,ll ,13-Dihydro,13-
dimethylaminoparthenolide 
maleate 
11S,ll ,13-Dihydro,13-
dimethylaminoparthenolide 
methiodide 
11S,ll ,13-Dihydro,13-
(4-methylpiperidin-1-
yl)parthenolide 
methiodide 
11H,13-(N,N-
Dimethylamino )-
dehydrocostuslactone 
11H,13-(N-Piperidine)-
dehydrocostuslactone 
11H,13-(N-Butyl-N-
methylamino )-
dehydrocostuslactone 
11H,13-(N-
Propylamino )-
dehydrocostuslactone 
11H,13-(N-Diallyl)-
dehydrocostuslactone 
11H,13-(N-
Morpholine)-
dehydrocostuslactone 
11H,13-(N-Pyrrolidine)-
dehydrocostuslactone 
11H,13-(N-Ethyl-N-
benzyl)-
dehydrocostuslactone 
11H,13-(N-Methyl-N-
propylamino )-
dehydrocostuslactone 
11H,13-(N,N-
Diethylamino )-
dehydrocostuslactone 
11H,13-(N-Methyl-N-
pentylamino )-
dehydrocostuslactone 
Reactants and Solvent 
11S,ll ,13-Dihydro,13-
dimethylaminoparthenolide 
(10 mg), HCl in ether 
(1M, 0.03 mL) 
11S,11,13-Dihydro, 13-
(pyrrolidin-1-
yl)parthenolide (5 mg), 
HCl in ether (1M, O.G15 mL) 
11S,11,13-Dihydro, 13-
(piperidin-1-
yl)parthenolide (5 mg), 
HCl in ether (1M, O.G15 mL) 
11S,11,13-Dihydro, 13-
(4-methylpiperidin-1-
yl)parthenolide (50 mg), 
HCl in ether (1M, 0.15 mL) 
11S,11,13-Dihydro, 13-
dimethylaminoparthenolide 
(30 mg), maleic acid 
(12 mg), ethanol (8 mL) 
11S,11,13-Dihydro, 13-
dimethylaminoparthenolide 
(30 mg), added 
iodomethane (90 mg), 
methanol (6 mL) 
11S,11,13-Dihydro, 13-
(4-methylpiperidin-1-
yl)parthenolide (70 mg), 
iodomethane (200 mg), 
methanol (12 mL) 
Example 10 
Reaction 
Conditions 
Refrigerator, 
24 hours 
Refrigerator, 
24 hours 
Refrigerator, 
24 hours 
Refrigerator, 
4 days 
Room 
temperature 
for 1 
week 
Room 
temperature 
for 3 days 
Room 
temperature 
for 3 days 
Analysis of Parthenolide and 
Dimethylaminoparthenolide (DMAPT) Using 
Human-Mouse Xenografts 
To assess the effect of parthenolide on primary human 
stem cell populations, experiments were conducted using 
transplantation into immune deficient NOD/SCID mice. 
Successful engraftment of NOD/SCID bone marrow at 6-8 
weeks post-transplant has been shown to be a measure of 
Yield Antileukemic 
(%) 
72 
10 
18 
38.3 
55 
86 
79 
activity 
10 f!M, 85% 
10 f!M, 88% 
10 f!M, 62% 
10 f!M, 12% 
10f!M, 14% 
10 f!M, 8% 
10 f!M, 24% 
10 f!M, 2% 
10 f!M, 10% 
10 f!M, 20% 
10 f!M, 13% 
10f!M, 1% 
10 f!M, 5% 
10 f!M, 0% 
stem cell content for human hematopoietic cell populations 
(Lapidot eta!., J Mol Med. 1997; 75: 664-673; Dick, Curr 
Opin Hematol. 1996; 3:405-409). For each experiment, 
60 cryopreserved mononuclear cell specimens from normal or 
AML donors were thawed, and treated in vitro with 7.5 
micromolar parthenolide for 12-18 hours. Following culture, 
5-10 million cells/animal were injected intravenously into 
sublethally irradiated (300 Rad) NOD/SCID mice. After 6-8 
65 weeks, animals were sacrificed and bone marrow was ana-
lyzed for the presence of human cells using flow cytometry 
as previously described (Guzman et a!., Proc Nat! Acad Sci 
US 9,447,112 B2 
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USA 2002; 99: 16220-162253). Human specific antibodies 
for CD45 were used to assess the level of total engraftment. 
32 
In three independent experiments, the level of engraft-
ment for parthenolide-treated AML cells was dramatically 
reduced, which indicates a direct effect on the AML stem 5 
cell compartment. In contrast, no reduction in engraftment 
was detected for parthenolide-treated normal specimens, 
thus showing the parthenolide does not target normal 
hematopoietic stem cells. Similarly, treatment of AML cells 
with 7.5 micromolar DMAPT also yielded a strong reduc- 10 
tion in NOD/SCID engraftment while treatment of normal 
cells showed no significant effects. 
parthenolide derivatives DMAPT, PIPT and 4MEPT for 
three hours. Cellular proliferation was reduced by up to 80% 
at 2 f.tm in the clonogenic assay (FIG. 1). The breast cancer 
cell line clonogenic assay with hbl-100, mdl-231 and 436 
cells showed almost complete inhibition of proliferation 
with DMAPT at 2 f.tm concentration in the clonogenic assay 
(FIGS. 6-8). Parthenolide also reduced proliferation with 
similar dosage ranges. 
Example 13 
eDNA Array Analysis 
Example 11 
MTS-PMS Assay 
A 96-well U-bottomed plate (Becton Dickinson Labware, 
Franklin Lakes, N.J.) at a concentration of 5,000 cells per 50 
microliters (mL) of media was incubated in 5% C02 at 37° 
C. for 24 hours. Varying compound concentrations in 50 mL 
of media were added to the media 24 hours later. Colori-
metric readings were obtained using the MTS/PMS system 
and an ELISA plate reader, after 48 hours of exposure to 
DMAPT. The readings obtained for each concentration 
tested were from an average of eight wells. Each experiment 
was expressed as a percentage of the solvent control and 
completed at least three times with consistent results. The 
results presented are an average of three experiments. The 
hormone refractory prostate cancer cell line CWR22Rv1 
was treated with increasing concentrations of parthenolide 
and DMAPT. for three hours Both parthenolide and DMAPT 
reduced cellular proliferation by 50% at 5 f.tm in the CWR22 
MTS-PMS assay. Cellular proliferation was also measured 
Total cellular RNA was extracted from the human mono-
cyte cell line THP-1 under three conditions 2 hours after 
15 Time 0: 
1) Control was added at Time 0 
2) Lipopolysacchride (10 nM) was added at Time plus one 
(1) hour 
3) At Time 0, 10 micromoles of DMAPT was added and 
20 
then at Time+ 1 LPS (1 0 nM) was added. 
RNA was extracted using RNeasy Min Kit (Qiagen, USA) 
according to the manufacturer's instructions. The Human 
Drug Targets for Inflammation and Immunomodulation Q 
series GE array kit (HS-048-12) was obtained from Super-
Array Bioscience Corporation (Frederick, Md.). The kit 
25 determines expression of 96 genes that are associated with 
inflammation. RNA from respective samples was used as a 
template to generate biotin labeled eDNA probes using 
GEArray Ampolabelling RT kit (SuperArray, Bioscience 
Corp., USA). The eDNA probes corresponding to the 
30 mRNA population were then denatured and hybridization 
was carried out in GEHyb solution to nylon membranes 
spotted with gene specific fragments. Membranes were then 
washed in 2xSSC, 1% SDS twice for 15 minutes each, 
followed by 0.1 SSC, 0.5% SDS twice for 15 minutes each. in the MTS-PMS assay using four lung cancer cell lines 
treated with parthenolide and derivatives PIPT ((11S,11,13-
dihydro, 13-(piperidin-1-yl)parthenolide ), 4MEPT (11 S,11, 
13-dihydro, 13-( 4-methylpiperidin-1-yl)parthenolide) and 
MAPT (11 S, 11, 13-dihydro, 13-dimethylaminoparthenolide ). 
Parthenolide and its derivatives inhibited cellular prolifera-
tion in a dose dependent manner between 2 and 10 f.LM with 
70% inhibition at 10 f.LM in A549, 50% in H460, 40% in 40 
H-23 and 40% in H522 (FIGS. 2-5). 
35 Chemiluminescence was used to visualize the expression 
levels of each transcript and the results were quantified with 
the GEArray Analyzer. The change in a given gene transcript 
was estimated by normalizing the signal intensities with the 
signal derived from PPIA and with minimum background 
subtraction. 
As can be seen in Table 3, transcription of 25 genes was 
increased after pre-treatment with LPS. More importantly 
pretreatment with DMAPT prevented or blunted the increase 
in gene transcription induced by LPS. For example, the 
transcription of tumor necrosis factor (TNF), released in 
Example 12 
Clonogenic Assay 
Initially, 100 cells growing in log phase were plated per 
3 ml of media in each well of a six well plate. After 24 hrs 
of plating of the cells the test compound was added at 
varying concentrations. At 24 and 96 hours after addition of 
drug, the media was changed. Hence, the cells were only 
exposed to the drug for 24 hrs. When cell colonies appeared 
at Day 15 they were stained by Sure Stain Dye and counted. 
The hormone refractory prostate cancer cell line 
CWR22Rv1 was treated with increasing concentrations of 
Gene 
45 septic shock, is increased by 3 fold (298%) when treated 
with LPS. Pretreatment with DMAPT however prevents 
transcription of LPS and in fact decreases its production to 
2% of control. Similarly, transcription of cyclo-oxygenase-
2, the target of classical non-steroidal anti-inflammatory 
so agents, was increased 1.5 fold (150%). In the presence of 
DMAPT, the gene expression not only prevented the 
increase by LPS but decreased it to 30% (0.7) of solvent 
control. DMAPT therefore may act to decrease inflamma-
tion by decreasing cytokines as evidenced by decreased 
genes in human monocytes 
TABLE 3 
eDNA Arra Anal sis 
LPS Treatment for 
1 hour: 
% Change of Gene 
DMAPT Pre-treatment for 
2 hours then 1 hour 
Treatment of LPS 
% Change of Genes 
CD28 antigen (Tp44) 23 
14 
0.814 
0.6 CD3G antigen, gannna polypeptide (TiT3 
complex) 
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TABLE 3-continued 
eDNA Arra Anal sis 
LPS Treatment for 
1 hour: 
DMAPT Pre-treatment for 
2 hours then 1 hour 
Treatment of LPS 
Gene % Change of Gene % Change of Genes 
Colony stimulating factor 2 26 
(granulocyte-macrophage) 
Intercellular Adhesion Molecule 1 257 
Interleukin 13 93 
Interleukin 1 receptor, type I 10 
Interleukin 1 receptor, type II 326 
Nitric oxide synthase 2A (inducible) 226 
Phosphodiesterase 4A, cAMP-specific 14 
Phosphodiesterase 4B, cAMP-specific 220 
Phospholipase A2, group IB (pancreas) 114 
Phospholipase A2, group IVC 350 
Phospholipase A2, group VII 129 
Phospholipase C, gannna 1 342 
Peroxisome proliferative activated receptor, 49 
gannna 
Platelet-activating factor receptor 32 
Prostaglandin D2 receptor (DP) 35 
Prostaglandin F receptor (FP) 879 
Cyclooxygenase 1 176 
Cyclooxygenase 2 152 
Thromboxane A synthase 1 283 
Twnor necrosis factor 298 
(TNF superfamily, member 2) 
Tumor necrosis factor (ligand) superfamily, 217 
member 13b 
Tumor necrosis factor (ligand) superfamily, 692 
member 5 
Vascular cell adbesion molecule 1 154 
Example 14 
Oral Bioavailability in Mice 
Preliminary in vivo work was conducted to determine the 
bioavailability and toxicity of this agent in mice. As shown 
in FIG. 4 it was demonstrated that whereas 40 mg/kg of oral 
parthenolide provided a plasma level one hour after oral 
gavage of only -200 nM, the same dose of DMAPT pro-
vided a plasma level of -2500 ng/mL (ie 8 f.lM-average of 
0.926 
58 
0.64 
0.33 
0.74 
48 
0.46 
0.59 
0.57 
0.89 
0.05 
0.24 
0.48 
0.002 
0.17 
1.46 
0.731 
0.7 
0.07 
0.02 
0.89 
23 
0.02 
Wis.). The specificity of parthenolide and derivative inhibi-
tion of NFKB DNA binding was verified by the use of the 
35 
SP-1 probe as a control. Identification of the NFKB subunits 
binding to DNA and inhibited by DMAPT were identified by 
gel supershift. Constitutive NF -KB DNA binding activity 
was determined in the lung cancer cell lines A-549, H-23, 
40 
H-522, and H-460. All four non-smalllung cancer cells were 
5 mice in each group; measured by LC-MS). Given the 
concern from providing such a high plasma concentration 45 
we completed a preliminary toxicity study that showed the 
mice gained weight and survived three weeks of daily 
treatment with oral DMAPT at 40 mg/kg with no overt 
treated with increasing concentrations of DMAPT for three 
hours, and NF-KB DNA binding was measured by electro-
phoretic mobility shift assay (EMSA) as described. NF-KB 
DNA binding activity was highest in A-549 cells, followed 
by H-23, H-522 and H-460 cells. DMAPT between 2 and 10 
micromolar substantially decreased NF -KB DNA binding 
activity in all lung cancer cell lines tested. 
toxicities. 
Example 15 
Electrophoretic Mobility Gel Shift Assay 
Each cancer cell line in exponential growth phase was 
treated with solvent control or various concentrations of 
parthenolide derivatives dissolved in 100% ethanol for 3 
hours prior to harvesting. Cells were harvested and whole 
cell extracts were prepared as described previously (Nak-
shatri eta!., Mol Cell Biol, 17: 3629-3639, 1997; Sweeney 
eta!., Clin Cancer Res, 10: 5501-5507, 2004). Extracts were 
incubated with a radiolabelled NFKB probe for 30 minutes 
at room temperature. The oligonucleotide probe binds to the 
NFKB DNA binding site in the promoter region of the 
immunoglobulin gene. Electrophoresis and autoradiorag-
raphy were performed as described previously (Nakshatri et 
a!., 1997) using NFKB and SP-1 probes (Promega, Madison, 
50 
Cancer cell lines HT-1376 and UMUC-3 were treated 
with increasing concentrations of DMAPT for three hours. 
Whole cell extracts were prepared as described and DNA 
binding by NF-KB was analyzed by EMSA with NF-KB and 
55 OCT-1 (internal control) probes. DMAPT decreased NF-KB 
DNA binding in a dose-dependent manner with HT-1376 
and UMUC-3 cell lines (FIG. 10). 
The hormone refractory prostate cancer cell line, 
CWR22Rv1 was treated with increasing concentrations of 
60 DMAPT for three hours. Whole cell extracts were prepared 
as described and DNA binding by NF -KB was analyzed by 
EMSA with NF-KB and SP-1 (internal control) probes. 
DMAPT decreased NF-KB DNA binding in a dose depen-
dent manner with substantial decreases of NF-KB DNA 
65 binding at 10 f.LM DMAPT. 
EMSA results thus showed DMAPT decreased the con-
stitutive NF-KB DNA binding in several cancer cell lines. 
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Example 16 
Pretreatment of Radiation Sensitive Cell Line A549 
The radiation sensitive celllineA549 was pretreated with 5 
parthenolide concentrations ranging from 0 to 2.5 micromo-
lar. The cells were then subjected to ionizing radiation doses 
ranging from 0-6Gy and survival fraction of the cells 
determined. Results demonstrated that parthenolide induced 
radiation sensitivity to the cells in a dose-dependent manner 10 
with survival fraction at 2.5 micromolar ranging from 10% 
at 2Gy to less than 1% at 6Gy. Cells not receiving pre-
treatment with parthenolide had greater than 50% survival 
fraction at the highest radiation dose of 6Gy and over 90% 
15 
survival at 2Gy. 
Example 17 
TRAIL Induced Apoptosis Assay 
20 
36 
Z is -CH2R * wherein R * is an amino acid residue 
bonded to the Z methylene via a nitrogen or a sulfur 
atom; orR* is -NR1C02-R
2
, 
-NR1C(O)NR2 , -S-R1 , or 
-N+R1R2R11Y- wherein 
R1 and R2 are independently selected from H, CN, and 
optionally substituted straight-chained or branched ali-
phatic optionally containing 1 or more double or triple 
bonds; wherein optional substituents are selected from 
one or more of -NH2 , -NH(C1 _4 aliphatic), -N(C1 _4 
aliphatic)2 , halogen, -OH, -O-(C1 _4 aliphatic), 
-N02 , ---CN, ---C02 H, ---C02 (C1 _4 aliphatic), 
---O(halo C1 _4 aliphatic), or -halo(C1 _4 aliphatic); 
wherein each C1 _4 aliphatic is optionally substituted; or 
R1 and R2 are independently selected from cycloalkyl, 
heterocycloalkyl, aryl or heteroaryl; and provided that 
R1 and R2 are not simultaneously H; or where R* is 
NR 1 R 2 , R 1 and R2 optionally together with the nitrogen 
atom form an optionally substituted 5-12 membered 
ring, said ring optionally comprising 1 or more het-
eroatoms or a group selected from -CO-, -SO-, 
and-S02-; 
R11 is selected from H or C1-4 aliphatic; and 
y- is selected from the group consisting of fluoride, 
chloride, bromide, iodide, sulfate, nitrate, bicarbonate, 
carbonate, acetate, citrate, malonate, tartarate, succi-
nate, benzoate, ascorbate, alpha-ketoglutarate, alpha-
glycerophosphate, methylsulfonate, toluenesulfonate, 
and benzenesulfonate; or 
a pharmaceutically acceptable salt thereof. 
2. The method of claim 1 wherein Z is -CH2-NR
1R2 . 
MDA-MB-231 breast cancer cells (2x105 cells in 60 mm 
plates) were treated first with 2 or 5 f.LM ofDMAPT (LC-1). 
After two hours, TRAIL (TNF related-apoptosis-inducing-
ligand, 5 ng/ml) or TRAIL-RII-activating antibodies (10 
25 
ng/ml) were added. After 48 hours of TRAIL or TRAIL-RII 
antibody treatment, cells were harvested and apoptosis was 
measured using carboxyfluorescein-FLICA assay. Briefly, 
both attached and floating cells were collected by trypsini-
zation, incubated with carboxyfluorescein-labeled pan-cas-
30 
pase inhibitor FAM-VAD-FMK for 2 hat 37° C. Labeled 
cells were rinsed twice in PBS and resuspended in 300 fll of 
PBS containing 0.3 flg of propidium iodide. Apoptotic cells 
were identified by FACScan analysis. Live cells do not stain 
(FIGS. 11 and 12) Lower left quadrant). FAM-VAD-FMK 
stains apoptotic cells (upper left). Apoptotic cells that have 
lost plasma membrane integrity are stained by both FAM-
VAD-FMK and propidium iodide (upper right). Necrotic 
cells are stained only by propidium iodide (lower right). 
MDA-MB-231 cells are relatively resistant to TRAIL. How-
40 
ever, they became sensitive to TRAIL or TRAIL-RII acti-
vating antibody-induced apoptosis and atypical apoptosis 
upon pre-treatment with DMAPT. 
3. The method of claim 2 wherein R1 and R2 are inde-
pendently selected from hydrogen, ---CN or optionally 
35 substituted C1 -C4 alkyl. 
The invention claimed is: 
1. A method of inhibiting cancer cell growth comprising 
administering to a mammal afflicted with a cancer selected 
from the group consisting of breast cancer, lung cancer and 
prostate cancer, an effective amount of a compound of 
formula (I): 
(I) 
z 
wherein: 
Xu X2 and X3 are 0; 
R5 , R6 , R7 , R9 , and R10 are H, and R4 and R8 are methyl; 
and 
4. The method of claim 3 wherein R1 and R2 are inde-
pendently selected from -N02 , ---CN, -CH3 , ---CF3 , 
---CH2 CH3 , ---CH2 CF3 , ---CH2 Cl, ---CH2 0H, 
---CH2 CH20H and -CH2NH2 . 
5. The method of claim 2 whereinR1 and R2 together with 
N form an optionally substituted ring. 
6. The method of claim 5 wherein said ring is a mono-
cyclic, bicyclic or tricyclic alkyl or aryl ring system, said 
ring system optionally substituted and optionally comprising 
45 one or more heteroatoms or a group selected from -CO-, 
-SO-, and -S02 . 
50 
55 
7. The method of claim 6 wherein R1 and R2 are 
-CH2 (CH2)nCH2 Y -; where Y is a heteroatom or a 
group selected from -CO-, -SO-, and 
-S02-; n is an integer 0 to 5; and together with N form 
an optionally substituted ring, said ring optionally 
fused to a cycloalkyl or aryl group to form a bicyclic or 
tricyclic ring system, said system optionally substituted 
and optionally comprising one or more heteroatoms. 
8. The method of claim 6 wherein R1 and R2 are 
-(CH2)a-Y-(CH2 ) 6-; where Y is a heteroatom or a 
group selected from -CO-, -SO-, and -S02-; a is an 
integer 0 to 5; b is an integer 0 to 5; the sum of a and b being 
0 to 5; and together with N form an optionally substituted 
60 ring, said ring optionally fused to a cycloalkyl or aryl group 
to form a bicyclic or tricyclic ring system, said system 
optionally substituted and optionally comprising one or 
more heteroatoms. 
9. The method of claim 6 wherein NR1 R2 is selected from 
65 optionally substituted aziridin-1-yl, azetidin-1-yl, pyrroli-
din-1-yl, piperidin-1-yl, homopiperidyn-1-yl and heptam-
ethyleneimin-1-yl. 
US 9,447,112 B2 
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10. The method of claim 1 wherein the compound of 
formula (I) is selected from: 
11 S, 11, 13-Dihydro, 13-dimethylaminoparthenolide; 
38 
liS, 11 ,13-Dihydro,13-( 4-(piperidin-1 '-yl)piperidin-1-
yl))parthenolide; 
liS, 11 ,13-Dihydro,13-diallylaminoparthenolide; or 
a pharmaceutically acceptable salt thereof. 11 S, 11, 13-Dihydro, 13-diethylaminoparthenolide; 
11 S, 11, 13-Dihydro, 13-(tert-butylamino )parthenolide; 
11 S, 11, 13-Dihydro, 13-(pyrrolidin-1-yl)parthenolide; 
5 11. The method of claim 10 wherein the compound of 
11 S, 11, 13-Dihydro, 13-(piperidin-1-yl)parthenolide; 
11 S, 11, 13-Dihydro, 13-(morpholin-1-yl)parthenolide; 
11 S, 11, 13-Dihydro, 13-( 4-methylpiperidin-1-yl)partheno-
lide; 10 
11 S, 11, 13-Dihydro, 13-( 4-methylpiperazin-1-yl)partheno-
lide; 
11 S, 11, 13-Dihydro, 13-(homopiperidin-1-yl)partheno-
lide; 
11 S, 11, 13-Dihydro, 13-(heptamethyleneimin-1-yl)parthe-
nolide; 
11 S, 11, 13-Dihydro, 13-( azetidin-1-yl)parthenolide; 
15 
11 S, 11 ,13-Dihydro,13-methylbutyl aminoparthenolide; 
11S,11,13-Dihydro,13-methyl pentyl aminoparthenolide; 20 
11 S, 11, 13-Dihydro, 13-ethylaminoparthenolide; 
11 S, 11, 13-Dihydro, 13-methylaminoparthenolide; 
11 S, 11, 13-Dihydro, 13-cyclopropylaminoparthenolide; 
11 S, 11, 13-Dihydro, 13-propargylaminoparthenolide; 
11 S, 11 ,13-Dihydro,13-(N-benzyl-N-ethylamine )parthe- 25 
nolide; 
11 S, 11, 13-Dihydro, 13-(N -prolyl)parthenolide; 
11 S, 11, 13-Dihydro, 13-(S-thiophenolyl)parthenolide; 
11 S, 11, 13-Dihydro, 13-(N,N -diethanolamine )partheno-
lide; 
11 S, 11, 13-Dihydro, 13-(thiomorpholin-4-yl)parthenolide; 
11 S, 11, 13-Dihydro, 13-( 4-hydroxypiperidin-1-yl)parthe-
nolide; 
11 S, 11, 13-Dihydro, 13-(1-methylhomopiperizin-4-yl)par-
thenolide; 
11 S, 11, 13-Dihydro, 13-(S-mercaptoacetyl)parthenolide; 
11 S, 11, 13-Dihydro, 13-( 4-(2'-hydroxyethyl)piperidin-1-
yl)parthenolide; 
11 S, 11, 13-Dihydro, 13-(piperazin-1-yl-4-carboxalde-
hyde )parthenolide; 
11 S, 11, 13-Dihydro, 13-( 4-benzylpiperidin-1-yl)partheno-
lide; 
11 S, 11 ,13-Dihydro,13-(piperidin-1-yl-4-carboxylic acid) 
parthenolide; 
30 
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40 
11 S, 11 ,13-Dihydro,13-(azetidin-1-yl-3-carboxylic acid) 45 
parthenolide; 
11 S, 11, 13-Dihydro, 13-(S-cysteinyl)parthenolide; 
formula (I) is 
11 S, 11,13-Dihydro, 13-dimethylaminoparthenolide; or 
a pharmaceutically acceptable salt thereof. 
12. The method of claim 11 wherein the compound of 
formula (I) is 
11 S, 11,13-Dihydro, 13-dimethylaminoparthenolide 
hydrochloride; or 
11 S, 11,13-Dihydro, 13-dimethylaminoparthenolide 
maleate. 
13. The method of claim 1 wherein the compound of 
formula (I) is selected from: 
liS, 11 ,13-Dihydro,13-(pyrrolidin-1-yl)parthenolide 
hydrochloride; 
liS, 11 ,13-Dihydro,13-(piperidin-1-yl)parthenolide 
hydrochloride; 
liS, 11 ,13-Dihydro,13-( 4-methylpiperidin-1-yl)partheno-
lide hydrochloride; 
11 S, 11,13-Dihydro, 13-dimethylaminoparthenolide 
methiodide; or 
liS, 11 ,13-Dihydro,13-( 4-methylpiperidin-1-yl)partheno-
lide methiodide. 
14 . . The method of claim 1 wherein Z is ---CH2S-R
1
; 
wherem 
R 1 is selected from optionally substituted straight-chained 
or branched aliphatic wherein optional substituents are 
selected from one or more of -NH2, -N(C1 _4 ali-
phatic)2, halogen, -OH, ---O-(C1 _4 aliphatic), 
-N02, -CN, -C02H, ---C02(C1 _4 aliphatic), -0-
(halo c1-4 aliphatic), or -(halo c1-4 aliphatic); wherein 
each C1-4 aliphatic is optionally substituted; cycloalkyl, 
heterocycloalkyl, aryl or heteroaryl. 
15. The method of claim 1 wherein Z is ---CH2S-R
1
; 
wherein 
R 1 is selected from optionally substituted straight-chained 
or branched aliphatic wherein optional substituents are 
selected from one or more of -NH2, -N(C1 _4 ali-
phatic)2, halogen, -OH, ---O-(C1 _4 aliphatic), 
-N02, -CN, -C02H, ---C02(C1 _4 aliphatic), -0-
(halo c1-4 aliphatic), or -(halo c1-4 aliphatic); wherein 
each C1-4 aliphatic is optionally substituted; cycloalkyl, 
heterocycloalkyl, aryl or heteroaryl. 
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